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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) hereby presents 
its sixteenth General report of activities to the European Parliament, the Council of the 
European Union, the European Commission, the Court of Auditors and the Member States, 
following its adoption by the Management Board.
The report provides an account of the EMCDDA’s activities and accomplishments in 2010, 
the first year within the EMCDDA three-year Work programme 2010–12.
From an institutional point of view, 2010 was marked by the first presentation of key findings 
of the Annual report on the state of the drugs problem in Europe to the Ministers of Justice at 
the Justice and Home Affairs Council on 9 November in Brussels, further to an invitation 
from the Belgian Presidency. This key event was prior to the public launch of the Annual 
report, which took place at the EMCDDA’s headquarters in Lisbon. The launch was followed 
by a presentation of the report to the European Parliament Committee on Civil Liberties, 
Justice and Home Affairs (LIBE Committee) by the Director.
As the report shows, this was another very busy and productive year for the agency. On a 
more personal note, as this was also my first year as Chair of the Management Board, I 
would like to express my gratitude to colleagues on the Management Board and members 
of the Scientific Committee for their support during this time, and their continued commitment 
to the objectives of the agency.
My special thanks also go to Director Wolfgang Götz, the staff of the agency as well as the 
Heads of the Reitox national focal points and their staff for their dedication and professional 
commitment to the results achieved in 2010.
 
João Goulão 
Chairman of the EMCDDA Management Board

9Introduction
This report provides a non-exhaustive account of the EMCDDA’s main activities and 
accomplishments in 2010. This is the first year of the agency’s new three-year strategy for 
2010–12 that will consolidate core data sets held by the EMCDDA to enable more complex 
analysis, a scaling-up of activities and work in new areas of strategic importance. The Work 
programme for the first year of the strategy is by definition formative and exploratory in 
nature, to set the foundations for the work to be developed in 2011 and 2012. Just as 2009 
was a year of change and new challenges, 2010 also had its fair share of changes, namely 
in terms of a major reorganisation of the agency’s scientific units. The new structure put in 
place will, I am sure, enable the agency’s staff to work more effectively in order to meet our 
demands and objectives. The success of the restructuring will be fully tested in 2011, but the 
major work undertaken in 2010 has already helped create new synergies.
This year’s General report of activities will present results by activity as set out in the 2010 
Work programme. The full text of each objective can be found in Annex 1 to the 
publication, for ease of reference. This format, already tested last year, ensures that the 
report is easy to read, but also makes it possible for readers to cross-check results in more 
detail against the objectives, should they wish to do so.
As 2010 marked the first full year of operations in our riverside offices, we are happy to see 
how the change has encouraged more proactive, dynamic relations between staff. It also 
seems to have attracted many official visitors from around the globe. I hope this will 
continue into 2011 and beyond.
I will conclude by drawing the reader’s attention to the fact that in 2010 the EMCDDA 
continued to produce not only high-quality products and outputs, but also developed its 
profile and scientific credibility. Such credibility and productivity can only be achieved with 
the support of the Management Board, Scientific Committee and Reitox network, as well as 
a team of expert and highly-committed staff from throughout the European Union. I extend 
my heartfelt thanks to every one of them.
 
Wolfgang Götz 
Director
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Chapter 1 
Overview
This report covers the first year in the EMCDDA s´ three-year strategy defined for 2010–12. 
The strategy builds on the progress made in the 2007–09 period and keeps the focus on 
the core tasks set out in the agency’s mandate.
As in previous years, we continued working closely with experts across Europe to improve 
the availability, quality and value of the data we use. At the same time, keeping pace with 
the changing nature of the European drugs problem and emerging information needs 
remains a key challenge. To address this, during the three years of the new strategy we will 
increase our efforts to improve the timeliness of our reporting. Priority will be given to better 
identify and promptly report on new trends, while keeping the balance between the need to 
report rapidly and the need to be accurate, non-alarmist and consistent. In line with the EU 
action plan on drugs 2009–12, the strategy places greater emphasis on best practice and 
ensuring quality in services delivery. Another priority area is the development of more 
refined indicators in the supply reduction field. Appropriate resources will continue to be 
devoted to strengthening our international cooperation and collaboration with partners, with 
a view to effectively communicate our results, share experience and avoid duplication of 
efforts. We will also refine our communication and dissemination strategy and revise 
internal tools and processes, in order to ensure that our products meet the needs of our 
target audience and that our work remains relevant and cost-effective.
In 2010, three transversal areas were at the heart of the agency’s mandate to provide 
factual, objective, reliable and comparable information: producing a state-of-the-art annual 
review of developments in drug use and responses in Europe; maintaining an up-to-date and 
high-quality online European reference point on drugs and providing ongoing support to EU 
institutions for implementing and monitoring the EU action plan.
In order to achieve the above, greater emphasis was placed on ensuring data quality and a 
more joined up and analytical approach to our work. This included new quality assurance 
measures and improved routines for ensuring the accuracy of all statistical analyses and 
data manipulations used for the annual reporting exercise. On the analysis side, priority 
was given to the cross analysis of indicator data, with a number of projects relying on the 
synthesis of different data sets.
Detecting and exchanging information on emerging trends to reflect the dynamic of the drug 
problem played an important role in the agency’s work in 2010. A record number (41) of 
new psychoactive substances were notified. In the framework of the Council Decision on 
new psychoactive substances, a Europol–EMCDDA Joint Report on mephedrone was 
prepared and submitted to the Council, European Medicines Agency (EMA) and the 
European Commission (EC). It was followed by the Report on the risk assessment of 
mephedrone, prepared by the EMCDDA and submitted to the EC and the Council.
The monitoring of drug supply and supply reduction activities was also improved in 2010. 
One of the key achievements was represented by the First European conference on drug 
supply indicators, jointly organised by the EMCDDA and the EC, with the active involvement 
of Europol.
In terms of methodological developments, the EMCDDA invested considerable efforts to 
ensure that reporting tools are methodologically sound and well structured. To this end, 
work to revise and rationalise the area of key indicators continued, in particular the 
indicators for treatment demand (TDI) and problem drug use (PDU). On the responses side, 
the work on developing a strategy for data collection and analysis of interventions data 
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commenced. This will eventually feed into the planned systemic review by the agency and 
also contribute to the implementation of the next five-year data collection cycle.
Significant energy was devoted to improving Europe s´ capacity to monitor and evaluate 
policies. A Reitox academy on the evaluation of national drug strategies and action plans 
took place, to allow for an exchange of information and experience and discuss ways to 
respond to common challenges.
To provide ongoing support to the EU drug policy review, 20 reports to the Commission on 
the EU drugs action plan for 2009–12 (thematic papers) were prepared in 2010, reviewing 
the progress achieved in implementing the plan.
Further work was carried out to develop sound foundations for supporting the establishment 
of European-level guidelines, frameworks and standards. To ensure effective operations, the 
EMCDDA s´ activities were closely synchronised with those carried out by the European 
Commission. To assist the process of developing quality guidelines, a Selected issue was 
launched in 2010, to review existing national guidelines and organisational frameworks in 
this area. The process was supported by a Reitox academy which provided national focal 
points (NFPs) with sound methodological support for data collection.
To further develop and encourage the exchange of information on evidence-based 
interventions, the Best practice portal was restructured and two new modules, on treatment 
and on harm reduction interventions, were released.
In the area of harm reduction, the EMCDDA’s 10th scientific monograph, entitled Harm 
reduction: evidence, impacts and challenges provides a significant and comprehensive 
overview of the harm reduction field, geared towards a broader audience including 
policymakers, healthcare professionals working with drug users, as well as the wider public.
The production of high-quality reports, articles and presentations received special attention 
in 2010. During the course of the year, 31 publications and 6 main website areas were 
published. In addition, 31 scientific articles prepared or co-authored by EMCDDA staff were 
published in various scientific journals and more than 95 presentations were given at 
scientific conferences and events. A new online resource, the ‘prevention profiles’, was 
launched and a new series of products, called ‘drug policy profiles’ started. Four issues of 
Drugnet Europe, the EMCDDA s´ quarterly newsletter, were released. The Annual report 
2010: the state of the drugs problem in Europe was launched in November 2010 and 
generated great interest from the part of both media and the public: more than 2 000 
media articles and over 16 000 Internet downloads in 2010 alone.
In terms of international cooperation, the EMCDDA continued to strengthen the transfer of 
know-how and best practice in monitoring the drug situation to international and regional 
partners, as well as third countries. Within the framework of the European Neighbourhood 
Policy (ENP), jointly with the European Commission, the agency organised the first seminar 
on the development of an EU drugs monitoring system, which gathered together 15 
European Neighbourhood Policy (ENP) countries. A Memorandum of Understanding (MoU) 
was signed with Ukraine setting up a framework for collaboration in collecting, analysing 
and disseminating information on drugs. To support partner countries, two joint publications 
were produced: The European Union and the drug phenomenon: frequently asked questions 
(1), published jointly by the EMCDDA and the European Commission, and Building a 
national drugs observatory: a joint handbook (2), published jointly by the EMCDDA and the 
Inter-American Drug Abuse Control Commission of the Organization of American States 
(CICAD–OAS).
(1) Available at: http://www.emcdda.europa.eu/joint-publications/eu-faq
(2) Available at: http://www.emcdda.europa.eu/publications/joint/ndo-handbook
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To ensure fruitful collaboration with European and international partners in the drugs field, 
regular contacts and coordination meetings were held with the agency’s institutional 
partners, such as the European institutions, other European agencies, international 
organisations, other organisations and bodies. On 15 November, the EMCDDA presented 
its Annual report to the members of the Committee on Civil Liberties, Justice and Home 
Affairs (LIBE) of the European Parliament. The cooperation with the Council of the European 
Union was mainly ensured through the Horizontal Working Party on Drugs (HDG), to which 
the agency contributed with expertise, information and drugs-related analyses.
The collaboration with the European Commission was further strengthened in 2010 and 
coordination meetings with DG JLS/DG Justice (3) and DG SANCO occurred throughout the 
year. One of the most notable events was the organisation of the First European conference 
on drug supply indicators, which took place in Brussels on 20–22 October. The conference 
was a joint venture between the European Commission and the EMCDDA, with the active 
involvement of Europol. The funding was mostly provided by the Commission.
The work with other EU agencies mainly focused on collaboration with the European Centre 
for Disease Control (ECDC), Europol, the European Medicines Agency (EMA) and the 
European Police College (CEPOL).
During 2010 there were a number of initiatives and joint projects with active contribution 
from the EMCDDA and ECDC, such as participation in technical meetings as well as the 
EMCDDA’s input to the report on the implementation of the Dublin Declaration on 
Partnership to Fight HIV/AIDS in Europe and Central Asia, and the exchange of information 
through the early warning system on the drug-related infectious diseases indicator (DRID). 
The joint EMCDDA–ECDC Threat Assessment on Anthrax among drug users was updated in 
2010.
Collaboration with Europol involved the ongoing exchange of information on new 
psychoactive substances notified through the early warning system, the annual coordination 
meeting and the joint publications prepared by the two agencies under the framework of 
Council Decision 2005/387/JHA. These included the 2009 EMCDDA–Europol Annual 
report on the implementation of the Council decision (Article 10), which was submitted to 
the European Parliament, the Council and the Commission and the Europol–EMCDDA Joint 
Report on mephedrone, submitted to the Council, the EMA and the EC. A formal Working 
arrangement between the EMCDDA and the EMA was signed by the Directors in June 
2010. Also in 2010, the EMCDDA was for the first time included in new pharmacovigilance 
legislation (Regulation (EU) No 1235/2010 of 15 December 2010, Article 28c).
On 1 March 2010, the EMCDDA took over the presidency of the Heads of Communication 
and Information Network (HCIN) of the EU agencies. In preparation for this role, it hosted 
the third annual meeting of the HCIN in Lisbon in February where the network discussed 
upcoming communication priorities and drew up the HCIN Work programme for 2010.
In 2010, the EMCDDA also worked closely with the United Nations Office on Drugs and 
Crime (UNODC), the World Health Organization (WHO), the World Customs Organization 
(WCO) and CICAD, as presented in detail in Chapter 3, Supporting drug policy dialogue 
and technical cooperation. Another highlight of the year was the new Memorandum of 
Understanding signed with the Council of Europe’s Pompidou Group during the latter’s 
Ministerial Conference in November 2010.
Particular attention was given in 2010 to the agency’s organisational framework, to ensure 
full support for the achievement of results. In this sense, the EMCDDA undertook an internal 
exercise of reviewing its structures, processes and behaviours. This resulted in the adoption 
(3)  On 1 July 2010, the Directorate-General for Justice, Freedom and Security (DG JLS) was split into the 
Directorate-General for Justice and Fundamental Rights (DG Justice) and the Directorate-General for Home 
Affairs.
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by the Director of a new unit-based organisational structure, which was endorsed by the 
Management Board. This structure should improve the agency’s organisational effectiveness, 
as well as the overall quality, rigour and relevance of its work and outputs.
The key new element of the structure was the reorganisation of the three former scientific 
units (Epidemiology, crime and markets – EPI; Interventions, law and policies – RES; and 
Scientific partners and documentation – SCD) into one Scientific division composed of four 
units called Interventions, best practice and scientific partners (IBS); Supply reduction and 
new trends (SAT); Prevalance, consequences and data management (EPI); and Policy, 
evaluation and content coordination (POL). This Scientific division (SDI) is headed and 
supervised by a Scientific Director, who reports to the Director of the EMCDDA.
The activities presented in this report would not have been possible without the support of 
the Reitox national focal points. The role of the EMCDDA and the Reitox network as 
catalysts and hubs for information exchange goes far beyond the annual reporting of data. 
Technical meetings and wider networking activities are vital for reporting but they also allow 
experts and practitioners to come together to share views and experiences. This knowledge 
exchange platform will be further developed in the coming years.
2
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Chapter 2 
Core business — monitoring and reporting on the 
drugs problem
The core business of the EMCDDA is to monitor and report on the drugs situation in Europe. 
The objectives defined in the Work programme for 2010 involve focusing on three 
transversal areas within the agency’s mandate to provide factual, objective, reliable and 
comparable information. These are:
1.  Producing a state-of-the-art annual review of developments in drug use and responses in Europe 
located within a broader explanatory conceptual framework (scientific, historical, demographical 
and socio-political).
2.  Maintaining an up-to-date and high-quality online European reference point on drugs.
3.  Providing ongoing support to EU institutions for implementing and monitoring the EU action plan.
Monitoring the drug situation
The aim of this component of the EMCDDA s´ Work programme is to produce an integrated 
and accurate overview of the extent and patterns of drug use in the European Union, of the 
consequences of use and of the determinants and correlates of drug use and drug-related 
problems, where possible.
To this end, a comprehensive set of key indicators and core data on different domains 
regarding drug use has been developed over the years, in close collaboration between the 
EMCDDA and the Reitox national focal points (NFPs), with technical input from external 
contractors and experts.
To ensure quality, reliability, harmonisation and validity of the information, a set of data 
collection tools and procedures has been developed. In addition to refining the basic 
information and indicators, new areas are being progressively developed and innovative 
analytical methods tested.
Tools and processes
The improvement of data management processes in order to deliver greater accuracy in 
qualitative and quantitative data sets [Objective 1.1.1] continued with the formalisation of 
the process for creating and checking templates, and the earlier delivery of these templates 
to the national focal points. Structured Query Language (SQL) programmes were further 
integrated into the data extraction process, improving efficiency, accuracy and 
standardisation of work practices.
The objective of harmonising and enhancing data management and data analysis, 
including formalising processes, improving computing tools and boosting data quality 
assurance [Objective 1.1.2] centred on the development of a data collection tool, which 
will be delivered in early 2011. One feature of this will be to automate the validation of 
the first submission of reports as well as a dashboard (toolbar) to allow users to better 
track their report submissions. Dialogue between the focal points and the EMCDDA 
helped refine various details in relation to data submissions. Diaries are now used to 
record significant data issues for each country. Cross-checking of data between sources 
— in particular the data collection submissions and the national reports — was started at 
the end of the year.
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Significant work was also undertaken for the maintenance and development of the agency’s 
web-based data collection instrument called Fonte (regular meetings to plan development, 
discuss external contracts, manage testing programmes, discuss day to day management 
and how and when to convey information to the NFPs). Two meetings were also held with 
focal point representatives in May and November. Repeated testing of new versions of 
Fonte, developed by an external contractor, was completed.
In 2010, the annual review carried out by the agency and embodied in the Annual report 
and associated products, namely the online Statistical bulletin, the Selected issues, Country 
overviews and Reitox national reports [Objective 1.1.3] included the implementation of 
quality assurance mechanisms. Thirty quality reports were prepared and sent to the focal 
points in the countries concerned. The aim of these reports was to give feedback on the 
data sent to the EMCDDA, including recommendations to focal points and their national 
networks on how to further improve data quality. This involved listing strong points and 
giving specific recommendations, as required.
As per every year, the draft Annual report was subject to a consultation process, involving 
the EMCDDA’s Scientific Committee and NFPs. 216 comments were received and 
incorporated in the final version of the report.
The Statistical bulletin — the data companion to the Annual report — presents the 
quantitative data provided by the national focal points on the drug situation in Europe, 
along with associated meta-data. As planned, this was published on the web on 15 July 
2010. It represented the final result of a long and involved work cycle that commenced in 
November 2008 involving the EMCDDA and the NFPs, designed to ensure data quality.
Events to launch the Annual report
The Annual report was launched at an EMCDDA press conference in Lisbon on 10 November. 
Presenting the report were EMCDDA Chairman João Goulão, Director Wolfgang Götz and Aurel 
Ciobanu-Dordea, Director for Fundamental Rights and Union Citizenship in the European 
Commission’s Directorate-General for Justice. To mark the occasion, the agency released a 
comprehensive, multilingual information package covering 30 countries. This package included the 
report itself (available in 22 languages) and two Selected issue publications in English on problem 
amphetamine and methamphetamine use and issues surrounding older drug users. Also available on 
the day were the 2010 Statistical bulletin, providing tables and graphs on the European drug 
situation, Country overviews presenting national drug situations ‘at a glance’ and Drug profiles on 
synthetic cathinones, khat and synthetic cocaine derivatives. Twelve additional launch events were 
organised in Member States and Norway. By the end of the year, the agency had registered 
16 349 downloads of the Annual report.
The report was also presented in Brussels to the Justice and Home Affairs Council, the European 
Parliament’s Committee on Civil Liberties, Justice and Home Affairs/LIBE and the Horizontal Working 
Party on Drugs of the Council of the EU.
In accordance with the Work programme, preparatory work also started for the 2011 
Annual report. The tools for the 2011 data collection exercise underwent minor revisions in 
collaboration with the NFPs and changes were made to improve the user-friendliness of the 
tools, namely by linking them to already published data (Statistical bulletin) in order to allow 
NFPs to check easily if any new developments need to be reported.
A more substantial revision was performed on the structured questionnaire on drug policy, 
evaluation and coordination. The revised questionnaire will allow the EMCDDA to develop 
drug policy analyses based on the most recent information available at national level. It will 
also support the evaluation of the EU drugs strategy and action plan.
Key indicators
In relation to supporting work on the key indicators, the 2010 Work programme refers to 
the need to maintain and develop a European expert network [Objective 1.2.1]. As 
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planned, expert meetings were held for all five key indicators, with the participation of 
national and invited international experts and networking activities were implemented on 
technical issues and the dissemination of information. Similarly, the key indicator gateway 
was updated with the most recent documents available and a restricted area for information 
exchange among expert networks was maintained. The EMCDDA also provided advice and 
detailed technical support to experts from candidate and potential candidate countries.
Various activities were implemented in relation to the need to increase the quality and 
comparability of key indicators [Objective 1.2.2]. Research and liaison with international 
experts was consolidated and two studies were launched to explore survey methods. The 
‘Drug versus health surveys’ project investigated the differences in methodologies and 
findings of the studies conducted in both contexts — health and drug use. A literature 
review and an expert survey were conducted among the national experts on the General 
Population Survey (GPS), in order to gain insight on the comparability of data obtained from 
the two types of studies.
In relation to the GPS, the objective set for 2010 was to promote the reporting of population 
surveys and encourage the collection of data on frequency of use. This was to be achieved 
through a review and improved collection of information and reporting of study methods; 
the initiation of routine data collection on frequency of use, utilising standard approaches 
and collaboration with ESPAD and HBSC, including providing support for the analysis of 
data [Objective 1.2.3].
To this end, an annual expert meeting on the ‘Prevalence and patterns of drug use among 
the general population’ indicator took place on 22–23 June at the EMCDDA in Lisbon. The 
meeting brought together experts from Member States, the European School Survey Project 
on Alcohol and Other Drugs (ESPAD) and the Inter-American Drug Abuse Control 
Commission (CICAD). During the meeting, an overview of the progress and results for 
2009–10 was provided and discussions held on methodological issues.
A ‘Questionnaire mapping’ project analysed the questionnaires used in the general 
population surveys conducted in the Member States in order to match them with the 
European Model Questionnaire (EMQ). This mapping is another step in the process to 
harmonise survey methodologies across Member States. Following two voluntary data 
collections, a routine data collection on frequency of cannabis use was also started, 
supported by a restricted access webpage.
The EMCDDA provided scientific input to the Austrian national Reitox academy on general 
population surveys, held on 8 November in Vienna with the aim of improving the Austrian 
GPS results. The EMCDDA made a presentation giving an overview of the general 
population surveys and presented the results of the Drug versus Health Surveys project.
The aims set for 2010 in terms of the Treatment Demand Indicator (TDI) include finalising 
and implementing the re-assessment process for this indicator started in 2008, the 
continuing implementation of the treatment prevalence project and improvements to analysis 
and presentation of data [Objective 1.2.4]. To this end, the 10th annual TDI expert meeting 
took place on 20–21 September in the EMCDDA’s premises. The meeting was dedicated to 
revision of the indicator, but also its state of progress, the use of TDI data for understanding 
the drug situation and the collection and analysis of TDI data in prison settings.
In relation to the re-assessment process, a proposal of the main issues to be revised in the TDI 
was made. A small working group of 10 experts was organised in March and a list of 
recommendations was drafted. These recommendations were analysed and discussed by the 
EMCDDA and national experts, in consultation with NFPs. More consultation with experts is 
planned in 2011, to conclude the revision process and develop the final TDI protocol proposal.
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Objectives for 2010 in relation to the Drug-related deaths indicator (DRD) included revising 
the mortality cohort protocol, exploring the possible use of information gathered from 
special registers and preparatory work on the Selected issue for 2011 entitled Mortality 
related to drug use: a comprehensive approach and public health implications [Objective 
1.2.5]. To this end, the annual DRD expert meeting took place on 11–12 November in 
Lisbon. The main aims of the meeting were to share information and discuss the state of 
progress of this indicator, recently released European data and new developments (based 
on data reported by Member States and presented in the 2010 Annual report and 
Statistical bulletin), and to discuss current activities and steps forward.
The revision of the mortality cohort protocol was initiated in 2010, with support from two 
external contractors. One of the key steps in the revision process was the workshop on 
mortality cohort studies, held in Lisbon on 1–2 July. Experts from nine countries provided 
comments on the current protocol developed in 2002. Four new countries joined the 
working group on analyses of mortality cohort studies. A follow-up workshop was organised 
during the DRD expert meeting in November. Based on the comments received from the 
experts, the revised protocol is being prepared and will be finalised in June 2011. The new 
mortality cohort protocol will help improve the comparability of data and will represent a 
reference document for all the countries reporting data on mortality cohort studies through 
the dedicated standard table.
The objective to explore the use of information collected through special registers continued 
in 2010, with support from an external consultant. Mapping the information available in the 
special registries, in order to define minimal common data sets, was finalised. The inventory 
prepared used data collected from the 15 countries participating in the survey.
In 2010, work started on the Selected issue on mortality mentioned above (a 2011 product), 
via a workshop organised by the UK focal point on 10 May. Guidelines were discussed at 
this event, and then finalised and sent to national experts with a copy to the heads of the 
national focal points.
In relation to the Problem drug use indicator (PDU), work continued to develop alternative 
estimates of problem drug use [Objective 1.2.6]. The current PDU indicator is under revision 
given the significant changes in the drug situation over the last 15 years, namely the 
increased presence of cannabis and cocaine on the drug market. In 2010, consultation led 
to listing the problems with the existing approach to PDU, drafting a proposal for revision, 
to be further developed in 2011. The annual expert meeting on problem drug use took 
place in Lisbon on 13–14 December.
Work on cannabis disorders monitoring in general population and school surveys moved 
into a phase of transnational validation, organised by the EMCDDA and national experts. 
The result was a draft European monitoring strategy and guidelines, based on the national 
work produced so far.
In terms of the Drug-related infectious diseases indicator (DRID), the objectives for 2010 
centred on updating the DRID protocol, conducting a comparative analysis of HCV trends, 
continued collaboration with partners such as ECDC, WHO, DG SANCO and an analysis 
of factors impacting on HIV and HCV incidence [Objective 1.2.7].
The expert meeting for this indicator, held in Lisbon from 11–13 October, included 
discussions and revision of the DRID data collection template on behaviour, to be completed 
in 2011. This is the fruition of a process that started with the ‘draft DRID protocol’ in 2006. 
The revised data collection tool will be submitted for formal approval from the heads of the 
national focal points during their meeting in May 2011.
Several data analyses were performed in 2010, partly with support from WHO/Europe, 
through the DRID modelling study group (‘European Study Group for Mathematical 
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Modelling and Epidemiological Analysis of Drug Related Infectious Diseases’), jointly 
coordinated by the EMCDDA and RIVM Netherlands. They resulted in various publications 
in peer reviewed journals.
Additionally, the EMCDDA DRID testing guidelines were finalised and launched on World 
AIDS day (1 December). Collaboration with key partners (ECDC, WHO, EC, UNAIDS, the 
UN reference group and national experts and institutions) continued during the reporting 
period and resulted in several outputs, including an article in The Lancet. Collaboration 
continued with ECDC, the EC and national partners regarding early warning on the anthrax 
outbreak in UK and Germany, including a 2010 update of the ECDC/EMCDDA joint risk 
assessment.
New developmental areas
The objective for improving data collection and data analysis on polydrug use and 
vulnerable groups [Objective 1.3.1] had seven main strands in 2010, ranging from: 
improving data collection on polydrug use; an assessment of children’s experiences with 
drugs; polydrug use among treated patients; the health consequences of polydrug use; 
mortality and morbidity in vulnerable groups; patterns and combinations of drug 
consumption in these groups and options of new data sources for improving estimations of 
problem drug use, health consequences and assessing new trends. Data collection on 
polydrug use was implemented and tested. A second field trial for data collection on 
polydrug use (including alcohol and tobacco) was launched in general population surveys, 
using scripts piloted within the harmonised database project. The results will be used to feed 
into our 2011 reporting. Significant progress was made with four EU countries to harmonise 
a core set of variables at national level.
The Thematic paper entitled Children’s voices: experiences and perceptions of European 
children on drug and alcohol issues (see Annex 4) was published in 2010. The paper gives 
an insight into some of the key drug and alcohol issues that affect children, as seen from 
their perspective and using their own words. Key statistics are presented under each section 
of the paper.
The 2010 Work programme objective linked to reviewing drug use in custodial settings set 
out to produce a scientific paper on drug use in prison and carry out an assessment of 
drug-related mortality in custodial settings [Objective 1.3.2]. Data collection on drug use in 
prison is being revised, and a draft conceptual monitoring framework is being prepared to 
underpin future data collection. Work started on these in 2010 will continue in 2011 and 
will include the development of an indicator to monitor drug use, drug-related health 
problems and drug services in custodial settings.
A paper on Ten years of monitoring drug use in prison populations in Europe – Issues and 
challenges was submitted to the Howard Journal of Criminal Justice and accepted.
In 2010, work in relation to the objective governing data collection and analysis activities 
on crime, drug supply and markets [Objective 1.3.3] set out to finalise guidelines on drug 
availability in population surveys with an additional field test; lay the groundwork for a 
cannabis market and production Insight (2011 output); reconstruct historical data on drug-
law offences and analyse information on drug couriers in Europe.
The field test of two new standard tables on drug availability in population surveys was 
launched and the reconstruction of historical data on law offences from the last 15 years also 
started. This activity will continue in 2011. Similarly, an analysis of the information available 
on cannabis production and markets in Europe started: this will become a 2011 product.
A survey on drug couriers, based on key informants, was carried out and finalised. The 
survey set out to improve the agency’s information base in the area of drug trafficking. 
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Working with an external consultant, the EMCDDA aims to present the results of the survey 
in a Thematic paper in 2011.
Analysis and innovative strategies
For 2010, the agency set itself a range of activities in order to meet the objective of 
performing cross-indicator analysis to ensure maximum value from the data available 
[Objective 1.4.1]. For example, a Selected issue entitled Problem amphetamine and 
methamphetamine use in Europe was published (see Annex 4). Using mainly TDI and PDU 
indicators, this paper provides a comprehensive overview of the history, health effects, 
supply and use of amphetamines in Europe, as well as describing their problematic use and 
health effects (for both short- and long-term use) and the responses to them in the European 
countries that are most heavily affected.
The 2010 Annual report also addressed the issue of the health consequences of drug use, 
presenting sections on the adverse health effects associated with the use of cannabis and 
cocaine, based on the most recent data available.
Another project on the subject of recent heroin trends in Europe, based on TDI data analysis 
in combination with other data sources and indicators was launched during the year. 
Similarly, cross indicator analyses were conducted in the framework of the Cross Unit 
Projects (CUPs) on treatment and prison respectively. Details of these are presented later in 
this report.
Concerning the Work programme objective on investigating alternative methods of data 
analysis [Objective 1.4.2], a project to devise a harmonised database structure involving four 
countries (Denmark, France, Cyprus and the UK) was launched. The project will help carry 
out joint analyses, fostering a better awareness of the different situations in the participant 
countries. Similarly, the European central DRID modelling dataset was expanded to an 
additional three more countries, reaching 16 individual study datasets in total. To further 
explore the potential of innovative data sources, the preparatory work for an expert meeting 
on the analysis of wastewater was carried out. The meeting will take place early 2011.
Monitoring responses, interventions and solutions applied to drug-
related problems
Data collection on availability, accessibility and characteristics of responses
For the 2010 objective of providing a high-quality and comprehensive review of 
developments in health and social responses [Objective 2.1.1] as well as improving 
methodological tools to heighten understanding of various ratings data [Objective 2.1.2], 
the main activities developed include a minor revision of the tools for the data collection 
exercise in the area of responses (in consultation with the NFPs) in order to make the tools 
more user-friendly — namely by linking them with already published data (Statistical 
bulletin).
The online treatment overviews, which provide information on the availability of drug-related 
treatment in 30 countries (the EU Member States, Norway, Turkey and Croatia) were 
updated with 2010 data. The overviews will be restructured in 2011 and a downloadable 
report will be produced.
Coherent and systematic set of response indicators in conceptual areas
One of the objectives under this heading in the 2010 Work programme is to develop a 
coherent and comprehensive strategy for data collection and the analysis of interventions 
data [Objective 2.2.1]. Work on developing a strategy towards an integrated concept of 
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monitoring intervention indicators started and several internal meetings were held. A 
concept paper was drafted, giving an overview of the current situation, a definition of key 
terms, a tentative framework for the areas and the subareas to be covered by the new 
strategy, instruments for data collection and implementation aspects. Work to develop the 
strategy will continue in 2011.
The objective relating to introducing an improved set of prevention and early intervention 
indicators [Objective 2.2.2] centred mainly on the launching of a new online resource 
called ‘prevention profiles’ (4). This part of the website contains information on the level of 
implementation of different prevention measures in 30 European countries. Each ‘profile’ 
consists of a structured overview of prevention measures in a country, according to the four 
main types of prevention: environmental strategies, universal prevention, selective prevention 
and indicated prevention. In addition, the data can also be displayed on a map of Europe 
to highlight differences and similarities between countries in this field.
Special attention was devoted to the section on environmental strategies, defined as 
‘prevention strategies aimed at altering the immediate cultural, social, physical and 
economic environments in which people make their choices about drug use.’ The section 
provides information on the regulatory framework within the EU, as well as data from 
relevant external research projects. These relate also to Objective 2.1.3 of the Work 
programme.
A number of activities took place to better understand the problems of treatment availability, 
provision and coverage with respect to different target groups and interventions [Objective 
2.2.3]. Insight gained through these activities will help to further develop the respective 
indicators. The review of the availability of social reintegration started in 2010, supported 
by external experts.
To obtain extra insight on treatment coverage, the EMCDDA organised the meeting called 
‘European exchange on the practice and current issues in opioid substitution treatment (OST) 
in general practitioners’ setting’ as a satellite event to the TDI annual expert meeting. It 
provided a forum for European scientists, experts and general practitioners (GPs) to 
exchange experiences regarding the provision of opioid substitution treatment in primary 
care settings, to help stimulate and develop a common European platform of knowledge on 
the regulations, practices and challenges faced by GPs when providing this treatment to 
problem opioid users.
Preparatory work was also undertaken for the meeting entitled ‘European exchange on the 
policies and practices in the treatment of cannabis-related problems’ which will investigate 
the availability of cannabis treatment in Europe in early 2011.
For the objective linked to harm reduction [Objective 2.2.4], 2010 was an ambitious year 
that saw the publication of the EMCDDA’s 10th scientific monograph entitled Harm 
reduction: evidence, impacts and challenges (see Annex 4). The monograph provides a 
comprehensive overview of the harm reduction field, including the emergence of harm 
reduction approaches and their diffusion. The report also contains current evidence and the 
impacts of harm reduction, illustrating how the concept has broadened to cover a wide 
range of behaviours and harms and a section on current challenges and innovations in the 
field. The monograph is designed for policymakers, healthcare professionals working with 
drug users, and the general public. More than 5 000 downloads of this publication took 
place in 2010, underlining its relevance and appeal to its target audience.
Work to define a set of relevant, coherent and feasible indicators on harm reduction led to 
the development of two main indicators: ‘Syringe availability’ and ‘Access to treatment’, to 
(4) http://www.emcdda.europa.eu/prevention-profiles
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be further refined. With a view to ensure a more systematic reporting on harm reduction 
responses, the structure for online harm reduction profiles was developed in 2010 and draft 
versions were prepared for all 30 countries. These will be completed in 2011.
The work towards mapping the availability and quality of low-threshold service provision 
was carried out and a geographical mapping of national services providers (NUTS 2-level) 
was conceptualised.
The Work programme also set the agency the task of developing a better understanding of 
the economic analysis of drug markets [Objective 2.2.5]. To this end, a pilot study on the 
collection of wholesale drug prices in Europe was implemented. This included developing a 
questionnaire with Europol and two rounds of data collection in 2008 and 2009. A second 
expert meeting on wholesale drug prices in Europe was organised in June by the EMCDDA 
with the support of the UK NFP and the Serious Organised Crime Agency (SOCA) to gain 
consensus on the questionnaire and the content of the pilot study. The meeting was attended 
by 26 national representatives from 20 countries, including 17 law enforcement agents and 
7 NFP representatives, and a Europol representative. Following the meeting, a revised 
version of the questionnaire and the draft of the pilot study were prepared and sent to the 
participants. The final report will be published in 2011.
In terms of improving data collection and reporting on responses to drug use, as well as 
drug users in prison settings [Objective 2.2.6], data collection activities are under revision 
and a draft conceptual framework for monitoring drugs issues in prisons is under 
preparation. The process will continue in 2011 and will include the development of an 
indicator to monitor drug use, drug-related health problems and drug services, as already 
mentioned.
Analytical framework for new methodological developments
The Work programme objective of further expanding cross indicator analysis between 
epidemiology and responses [Objective 2.3.1] involves considering conceptual approaches 
to better link the indicators for situations and responses, using specific topics and target 
groups for cross indicator analyses. Two examples of this approach are older drug users in 
treatment and the cost of treatment respectively.
2010 saw the publication of a Selected issue entitled Treatment and care for older drug 
users. This output documents the ageing phenomenon linked to drug use now commonplace 
in Europe. It also aims to describe the drug use, health and social characteristics of older 
drug users in order to identify their health and social needs. Current policies, practices and 
the availability of health and social responses for older drug users in Europe are also 
presented and discussed. Work began on a Selected issue on the cost of drug-related 
treatment in the European Union, to be released in 2011.
The final objective set for 2010 in this area is to improve estimates of non-labelled public 
expenditure and develop modelling approaches for the economic analysis of the drugs 
phenomenon [Objective 2.3.2]. To this end, the EMCDDA participated in the fourth Annual 
Conference of the International Society for the Study of Drug Policy, which took place in the 
United States on 15–16 March. The theme of the conference was ‘The future of drug policy: 
trends in policy, research to practice and practices that should be researched.’ One of the 
topics that generated great interest at the event was the impact of the economic recession 
on the drug phenomenon, to which the EMCDDA contributed by presenting the report to the 
Commission on the action plan (thematic paper) on ‘Unemployment and drug treatment’.
The report to the Commission (thematic paper) ‘Modelling disorganised crime: the cannabis 
market’, was published in a special issue of the Bulletin on Narcotic Drugs. This follows on 
from a presentation made at the Third Annual Conference of the International Society for 
the Study of Drug Policy in Vienna in March 2009.
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Monitoring new trends and developments and assessing the risks of 
new substances
Implementation of early warning mechanism
2010 was also an important year in terms of actions linked to the Council Decision on the 
information exchange, risk assessment and control of psychoactive substances  
(2005/387/JHA) [Objective 3.1.1].
During the year, the EMCDDA continued to ensure the ongoing implementation of the early 
warning system (EWS), together with Europol and its EWS partners in the Member States, 
the Reitox network. As in previous years, and in order to ensure transparency in the 
implementation of the Decision, the EMCDDA and Europol prepared the 2009 EMCDDA–
Europol annual report on the implementation of the Council Decision (Article 10), which was 
submitted to the European Parliament, the Council and the Commission.
Daily communication led to timely notifications of new substances by the network, backed 
by the EMCDDA which provided analytical data sets, toxicological profiles and the relevant 
scientific literature. As a result of this work, 41 new psychoactive substances (the highest 
number ever reported) were notified in 2010. This represents an increase of more than 70 % 
from 2009. 41 new substance profiles were prepared by the EMCDDA and included in the 
European database on new drugs (EDND). Moreover, all the substance profiles in the 
database (160 in total) were regularly updated from the point of view of seizures, 
intoxications, analytical data and alerts.
In 2010, the EMCDDA continued the ongoing implementation of longer-term monitoring of 
new psychoactive substances by means of analysing the progress and the final biannual 
reports submitted by the EWS partners. In addition, more than 10 public health early 
warnings and subsequent follow-up, related to unusual hazards of occurrences of controlled 
(heroine, cocaine, etc.) and new drugs were prepared and distributed within the EWS 
network.
In 2009, the EMCDDA and Europol agreed at their joint annual meeting that mephedrone 
warranted a joint report, in accordance with the guidelines for launching such reports. 
Subsequently, data on mephedrone was collected from the Member States using 
questionnaires, and the resulting Europol–EMCDDA Joint report on mephedrone was 
prepared and submitted to the Council, European Commission and European Medicines 
Agency. Conversely, in the 2010 annual coordination meeting held in The Hague on 26 
November, the EMCDDA and Europol agreed that no substances met the necessary criteria 
to prepare a joint report in 2011.
Based on the analysis of the Joint report, the Council decided that the health and social 
risks of mephedrone should be assessed. A risk assessment exercise on mephedrone was 
therefore conducted by the EMCDDA, involving the agency’s staff, members of the Scientific 
Committee and additional scientists from Member States. The Reitox EWS network was also 
asked to contribute, by filling in questionnaires on the use of mephedrone in the Member 
States. The Report on the risk assessment of 4-methylmethcathinone (mephedrone) in the 
framework of the Council Decision on new psychoactive substances was prepared by the 
EMCDDA and submitted to the Commission and to the Council. It provides a risk assessment 
of the health and social risks caused by the use of, the manufacture of, and traffic in, 
mephedrone, the involvement of organised crime and possible consequences of control 
measures. The report includes the Technical report on mephedrone, Mephedrone: 
assessment of health risks and harms, and Mephedrone: additional studies — Overview of 
prevalence, use patterns, and effects. To support the preparation of the report, the EMCDDA 
operating guidelines for the risk assessment of new psychoactive substances published in 
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2010 were implemented for the first time. Based on the risk assessment report, at the end of 
2010, the Council adopted a decision on submitting mephedrone to control measures 
throughout Europe (Council Decision 2010/759/EU).
In addition, the EMCDDA is currently assisting the Council and the Commission with the 
assessment of the operational aspects of Council Decision 2005/387/JHA. In 2010, several 
meetings took place to provide input to the assessment and the EMCDDA contributed to 
developing the questionnaire sent to the Member States on this issue. This will be used to 
carry out an assessment in 2011.
The EMCDDA’s activities in the area of new drugs generated considerable interest from the 
media. As a result, more than 30 television, radio and press interviews on new drugs, 
‘legal highs’ and mephedrone were given to European media (TVI, BBC, The Guardian, 
The Wall Street Journal, Wales online, Irish Sunday Mirror, EU Observer, Diário de 
Notícias, Público Spain, Público Portugal, El País, Metro France, Radio TSF, and Europe 1, 
to name but a few).
In relation to the Work programme objective of exploring new sources, improving the 
European database on new drugs and enhancing the link with forensic science [Objective 
3.1.2], three new drug profiles were published online in 2010: synthetic cathinones, 
synthetic cocaine derivatives and khat (5). This brings the total number of substances in the 
drug profiles to 17. These are updated with latest figures available each year and are 
available in English, French and German.
In relation to exploring new sources of information, the network of wastewater analysis 
experts was re-convened. An expert meeting on the theme of ‘The use of wastewater 
analysis as a potential tool for monitoring illicit drugs’ was prepared and will take place 
early 2011.
In order to enhance the forensic science link, the EMCDDA is part of the steering group of 
the European network of forensic science institutes (ENFSI). Within this framework, the 
agency holds regular exchanges of information and expertise, in the context of the early 
warning system mechanism and in 2010 participated in the network’s annual meeting.
Work to ensure effective information exchange with the EMCDDA’s partners in the area of 
new drugs (Reitox early warning system network, Europol and the European Medicines 
Agency) [Objective 3.1.3] continued in 2010. The 10th Annual meeting of the Reitox early 
warning system network took place in Lisbon on 3–4 June 2010. The meeting was attended 
by representatives of the national focal points, Europol, the EMA and DG Justice of the 
European Commission.
In 2010, the collaboration with Europol involved the ongoing exchange of information on 
new psychoactive substances notified through the early warning system, the annual 
coordination meeting and the joint publications prepared by the two agencies under the 
framework of the Council Decision 2005/387/JHA.
The EMCDDA and the European Medicines Agency regularly exchange information, work 
on formal reports on new psychoactive substances and also ad hoc reports on misused 
medicinal products, to complement the reporting via the EU Pharmacovigilance system. In 
2010, for the first time the EMCDDA was explicitly included in new pharmacovigilance 
legislation (Regulation (EU) No 1235/2010 of 15 December 2010, Article 28c).
In order to further develop the collaboration between the two agencies, a formal Working 
arrangement was signed by the Directors in June 2010, to help encourage cooperation and 
the exchange of information.
(5) http://www.emcdda.europa.eu/publications/drug-profiles
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Emerging trends
The 2010 Work programme set out to further develop an integrated approach for 
monitoring and reporting on emerging trends [Objective 3.2.1]. To this end, a conceptual 
framework and strategy for data collection, monitoring and information exchange on 
emerging drugs trends was prepared.
Preparatory work on a case study on Diffusion and patterns of spread for new psychoactive 
drugs in Europe (including mephedrone, 1-benzylpiperazine (BZP) and 1-(3-chlorophenyl)
piperazine (mCPP) also took place during the year.
In terms of piloting new data sources and the trend spotting network [Objective 3.2.2], the 
EMCDDA developed further and implemented an exercise to monitor the market of the legal 
highs available on the web. A steering group was set up to develop a conceptual 
framework and methodology for structured Internet monitoring. A paper on EMCDDA 
Internet monitoring methodology and results was drafted and a group set up to carry out a 
‘snapshot’ of the online availability of ‘legal highs’ (primarily ‘Spice’, kratom, salvia and 
Hawaiian baby woodrose, GHB/GBL and hallucinogenic mushrooms). The snapshot 
identified a total of 170 online drug shops selling the aforementioned products, shipping 
them within the EU. Following this, a methodological review was undertaken and the key 
findings and recommendations were presented in the aforementioned paper: these will be 
used to improve future web monitoring. A second multilingual snapshot was performed in 
July 2010, to assess the online availability of mephedrone. Furthermore, English language 
snapshots were carried out in the course of the year on other products and substances 
(including naphyrone, MDAI).
In 2010, a study entitled Conceptualisation of a methodology for monitoring the misuse of 
medicines was launched. This will be released in 2011.
Improving Europe’s capacity to monitor and evaluate policies
Monitor and support tools to assess drug policies
In 2010, the EMCDDA continued to support Member States in evaluating their national 
strategies and action plans [Objective 4.1.1]. A Reitox academy took place in Lisbon on 
17–18 June for the exchange of information and experiences on evaluation and to discuss 
how to face common challenges. A total of 37 experts from over 30 countries attended the 
course, including delegates from non-Member States. During the academy, experts gave 
presentations and shared information and experiences. The EMCDDA will use the 
information gathered during this academy to develop European guidelines for the evaluation 
of national drug strategies and action plans. The outline of the guidelines was prepared in 
2010 and the content will be developed in 2011, to be published in 2012.
In 2010, the EMCDDA also started work on a new series of products called ‘Drug policy 
profiles’. The objective of this series is to describe the main characteristics of national drug 
policies with the aim to help readers — from researchers to policymakers — to better 
understand how Member States control drugs and respond to drug-related security, social 
and health problems. The first publication in the series will be the national policy profile for 
Portugal, to be released in 2011.
In relation to the Work programme objective linked to reporting of public expenditure, the 
cost of interventions and cost-effectiveness [Objective 4.1.2], the EMCDDA started the 
process of reviewing the data available and developed a proposal for a new data 
collection and analysis strategy. This document will be drafted in 2011 and its content will 
be discussed with the NFP coordinators in May 2012. This also relates to Objective 2.1.4 in 
the Work programme.
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In terms of increasing analysis of national laws and the legal basis for interventions in order 
to enhance their visibility [Objective 4.1.3], the EMCDDA continued to work with legal 
correspondents in order to update and expand the data contained in the European legal 
database on drugs (ELDD) — the agency’s online database of information on drugs-related 
legislation. A new Topic overview called ‘Threshold quantities’ was included in the ELDD 
and three other Topic overviews entitled Use, Treatment alternatives and Driving were 
updated in 2010. A legal country profile for Croatia was also created, covering the 
development of legislation, classification of substances, drug use and possession, trafficking 
and drug-related crime, prosecution and practice, prevention, care and treatment, 
precursors, money laundering and confiscation and new developments. Similarly, a ‘Review 
of methodologies of evaluating effects of drug-related legal changes’ was developed and 
included in the database. This	review	collected	and	analysed	existing	scientific	and	grey	
literature	on	the	consequences	of	drug	law	changes	in	order	to	understand	and	categorise	their	
approach	and	methodologies,	in	order	to	perform	more	objective	and	effective	future	
evaluations	of	such	changes.
The annual Legal Correspondents Meeting was organised in Lisbon on 21 June 2010. It 
focused on the different definitions of organised crime, in preparation for a new Topic 
overview.
A policy briefing on Responding to new psychoactive substances was drafted and will be 
published in 2011.
Ongoing support to the EU drug policy review [Objective 4.1.4] was also provided, in the 
form of thematic papers presenting the progress achieved in the implementation of each 
action in the policy. These include: Reitox national reports; the key epidemiological 
indicators; relevant surveys conducted in the Member States and the Commission’s progress 
reviews.
In total, 20 reports to the Commission on the action plan (thematic papers) were prepared 
in 2010. A trend report on the drug situation and drug-related responses covering the 
period from 2004 to the latest data available will be prepared by the EMCDDA, 
contributing to the evaluation of the EU Drugs strategy 2005–12. The focus of the report, to 
be delivered in June 2011, will be on the main trends and the main regional differences in 
the 27 Member States. Under this framework, the report will present the main changes in 
EU drugs monitoring, drug use and drug-related problems, developments in the areas of 
drug supply, drug policies and demand reduction. A comparison with the situation in the 
United States, Canada and Australia will also be presented in due course.
Good practice, guidelines and quality standards
The Work programme objective of further developing and encouraging the exchange of 
information on evidence based interventions [Objective 4.2.1] involved a restructuring of the 
agency’s Best practice portal (6) in order to make it more user friendly. A complete set of 
national treatment guidelines were also published on the portal. 
The EMCDDA also published the Prevention and evaluation resources kit (PERK) manual (see 
Annex 4). This compiles evidence-based prevention principles, planning rules and evaluation 
tips. It also includes related documentation and references to help readers access scientific 
prevention literature.
Similarly, the best practice treatment module was released. This section of the portal 
presents key evidence on the most common treatments offered to illicit drug users. The 
information is organised according to client profile, around the main substance of use. A 
(6) http://www.emcdda.europa.eu/best-practice
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harm reduction interventions module was also released, presenting the available information 
on the effects of specific interventions that are currently provided to drug users in Europe.
An expert meeting was held in Lisbon on 17 November 2010. This included the Chairman 
of the EMCDDA Management Board, members of the Scientific Committee, policymakers 
and top-level researchers in the areas of treatment, prevention and harm reduction. The 
participants agreed on a definition of best practice in the field of drug demand. A 
workshop on the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system was also organised in December 2010 for all EMCDDA staff, to present the 
methodology used to grade the evidence published on the Best practice portal.
To further develop and encourage exchange of experience on evidence-based interventions, 
the EMCDDA also initiated a reflection among the NFPs on their role in disseminating 
information on best practice at national level, as well as understanding the needs for 
information of professionals working in the drugs field. This initiative will be further 
developed in 2011.
To contribute to the identification and establishment of European quality standards and 
benchmarks for interventions [Objective 4.2.2], the EMCDDA was a member of the steering 
group of the Study on the development of an EU framework for minimum quality standards 
and benchmarks in drug demand reduction (EQUS), funded by the European Commission. 
The national treatment guidelines developed by the agency were the starting point for the 
project.
The EMCDDA also collaborated as partner in the project on European standards in 
evidence for drug prevention, funded by the European Commission under its Programme of 
Community Action in the field of Public Health (2003–08). The project, which ended in 
2010, defined minimum standards for prevention programmes which will support 
professionals to deliver evidence-based practice in prevention.
The intermediate and final results of the two projects were published on the Best practice 
portal. More results from the EQUS project will be added in 2011.
In preparation for the Selected issue on History, methods and implementation of national 
treatment guidelines, to be published in 2011, a Reitox academy called ‘Towards the 
Selected issue 2011: history, methods and implementation of national treatment guidelines’ 
was held in 2010. The Academy brought together around 40 experts from 30 countries, 
including first-time attendees Albania, Bosnia and Herzegovina and Montenegro.
Cross-unit projects (CUPs)
Three cross-unit projects (CUPs) were set up in July 2010. These ensure the coordination of 
transversal activities within the agency in the field of treatment, prisons and modelling 
respectively. Each CUP has a dedicated team of EMCDDA scientific staff, led by a 
coordinator and supervised by a Head of unit. The CUPs have clear terms of reference and 
well defined objectives and expected outcomes.
Treatment
The treatment CUP was created as a platform to facilitate communication between staff 
working in the treatment area, to ensure a coherent approach to monitoring and reporting 
on this area within the agency, facilitating cross indicator analyses. The main objective of 
the CUP is to develop and implement a data collection and analysis strategy on treatment 
and related areas. In this respect, the treatment CUP takes over the work performed by the 
treatment working group, set up in 2007. In 2010, the detailed work plan for 2011 and 
strategic outlook for 2012 were elaborated and five meetings held.
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In terms of scientific outputs, one of the objectives of the Treatment CUP is to enhance the 
EMCDDA’s capacity to provide high quality information and analyses on treatment related 
aspects. In order to improve understanding of treatment coverage, the following analyses 
were undertaken:
•  analysis of technical specifications and characteristics of national treatment databases: 
TDI, opioid substitution clients’ registries;
•  mapping and analysis of web-based treatment inventories (online treatment facility 
databases) – 30 country profiles were defined (the Member States, Norway, Croatia and 
Turkey);
•  identification of inter linkages as well as overlaps in data collection on clients treated by 
GPs;
•  exploration of current options for standardised EU-wide analyses of treatment-related 
datasets, and for harmonising national database structures;
•  the potential of the information in national online treatment inventories regarding the 
assessment of TDI coverage at country level will be further explored.
In order to improve the scientific exchange on treatment monitoring in Europe, the CUP 
maintained contacts with external partners, including WHO, the Pompidou Group and the 
European Commission. It also attended various steering committees of European projects in 
this field.
Drug supply and supply reduction
The former CUP on drug supply and supply reduction ended in 2009. In 2010, due to the 
reorganisation of the scientific units, the work in the area of drug supply and supply 
reduction [Objective 5.2.1] was assigned to the newly created Supply reduction and new 
trends unit (SAT).
In 2010, the major event in the area of supply reduction was the ‘First European conference 
on drug supply indicators’, held in Brussels on 20–22 October. The conference was a joint 
venture between the European Commission and the EMCDDA, with the active involvement 
of Europol. Funding was mostly provided by the Commission. The main goal of the 
conference was to launch the work needed to establish a set of technically sound and 
sustainable indicators for monitoring drug markets, crime and supply reduction in the EU. 
From this perspective, the event represented an important first step towards achieving the 
objectives stated in the EU drugs action plan (2009–12). The conference was organised 
around three main thematic areas: the drug market, the drug-crime nexus and drug supply 
reduction. It brought together 120 participants, including law enforcement officials, forensic 
scientists, academics, experts and data analysts from national and international institutions.
The work started at the conference will be taken forward in 2011 through the setting-up of 
three technical working groups in the areas of markets, crime and supply reduction. The 
EMCDDA will help to establish and support these groups. A consensus conference is 
planned for 2012, to adopt the proposals developed by the working groups (7).
A mapping exercise on drug law enforcement started in 2010, to provide an overview of 
the number, institutional affiliation and mandate of Europe’s specialised drug law 
enforcement units. This will be followed by a survey in 2011.
A project on retail prices initiated in 2008 resulted in the publication in 2010 of a Manual 
called Guidelines for collecting data on retail drug prices in Europe: issues and challenges 
(see Annex 4). The main objective of the Manual is to raise awareness on a series of key 
(7)  For conference conclusions, see http://www.emcdda.europa.eu/publications/supply-indicator-
conference-2010/conclusions
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issues related to collecting retail drug prices data. It reviews the main methods of data 
collection in Europe, together with examples from current national practices. It also 
addresses some practical topics linked to data management and analysis.
A market analysis joint publication was published with Europol, entitled Cocaine: a 
European Union perspective in the global context (see Annex 4).
Prison
The aim of the prison CUP is to coordinate and scale up the agency’s work on monitoring 
the prison setting [Objective 5.3.1]. In line with the EMCDDA’s mandate, the team focused 
on evaluating the availability of information on drugs in prison (drug use and its health and 
social consequences, treatment and other health care services), in order to develop realistic 
proposals for improvement. Special attention is being given to the actions in the EU drugs 
action plan for 2009–12 for which the EMCDDA is required to provide input. Three prison 
CUP coordination meetings were held in 2010.
During 2010, work started on mapping previous and current activities and projects in the 
field, to try and avoid duplication of effort. The staff concerned therefore maintained 
permanent contact with external partners, including WHO, the Pompidou Group and the 
European Commission. Related topics were also followed up in the HDG meetings and with 
the European Commission’s DG Justice. Guidelines for the 2012 Selected issue on drug-
related health policies and services in prison were prepared and presented at the Reitox 
heads of focal points meeting in November 2010. A Reitox academy will be dedicated to 
this theme in 2011 and preparatory work for the Academy started in 2010.
Modelling
In respect to the objective of improving capacity for developing statistical and mathematical 
models of drug use, consequences and intervention effects [Objective 5.4.1], the modelling 
CUP was launched in July. Two coordination meetings were held in 2010, during which the 
draft terms of reference were developed and the Work programme for 2011 was drafted. 
The focus here will be on research questions rather than on describing models and methods. 
In this sense, an inventory of papers planned or in progress at the EMCDDA was carried 
out to facilitate selection of suitable research questions. Several joint analyses and activities 
were proposed for potential development during 2011, including new work on meta-
analyses and heroin incidence estimation as well as providing in-house support and peer 
exchange for scientific papers.
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Chapter 3 
Supporting drug policy dialogue and technical 
cooperation
International cooperation and collaboration with partners
In line with its strategy for international cooperation, the EMCDDA continued to strengthen 
the transfer of know-how and best practices in monitoring the drug situation to international 
and regional partners, and to third countries [Objective III.1.1].
In terms of cooperation with European neighbourhood countries, in 2010 the EMCDDA and 
the European Commission jointly organised the first seminar to explore the perspectives for 
technical cooperation between the EMCDDA and the European Neighbourhood Policy (ENP) 
beneficiary countries. This brought together 15 ENP countries. A follow-up meeting took place 
with some of the southern partnership countries (Algeria, Egypt, Jordan, Lebanon and 
Morocco) during the Pompidou Group MedNet Seminar.
Preparatory work for the signing of a Memorandum of Understanding (MoU) with Morocco 
took place in 2010 and Algeria officially asked to explore further possibilities for 
cooperation with the agency.
In terms of countries from the eastern partnership (Armenia, Azerbaijan, Belarus, Georgia, 
Moldova and Ukraine), following the mandate given by the EMCDDA Management Board, 
on 28 January the EMCDDA Director signed a Memorandum of Understanding between the 
EMCDDA and the Ukrainian Ministry of Health in Kiev. This aims to set up cooperation 
between the competent bodies in Ukraine and the EMCDDA in collecting, processing and 
disseminating information on drugs, as well as to continue the work on further developing 
joint methods for monitoring illicit drug use and to elaborate and improve joint harmonised 
indicators of drug situation monitoring and evaluation systems. On the basis of this MoU, 
Ukrainian experts attended the EMCDDA’s early warning system expert meeting in June.
In 2010, the EMCDDA produced two publications targeted at partner countries (see Annex 
4). The European Union and the drug phenomenon: frequently asked questions was 
published with the European Commission in English and French. It provides information on 
some of the key questions on the EU’s drugs policy and how it functions. Further language 
versions have since been published.
The second product, called Building a national drugs observatory: a joint handbook was 
published jointly by the EMCDDA and the Inter-American Drug Abuse Control Commission 
of the Organization of American States (CICAD–OAS). The handbook is a practical guide 
for developing National Drug Observatories (NDOs) in all world regions. The handbook is 
structured in thematic sections devoted to the process of building or consolidating a national 
drugs observatory. An ‘online toolbox’ with additional bibliographic references, templates 
and practical guidelines is also provided. The handbook — available now in seven 
languages — was launched at the CICAD International meeting of national drug 
observatories as a key reference for international partners. The publication was also 
promoted and disseminated at the Pompidou Group MedNet Seminar.
The work on building national drug observatories was further developed with the 
organisation of a Reitox academy organised in Lisbon by the EMCDDA in collaboration with 
the Presidency of the Council of Ministers of Italy (Antidrug policies department) at the 
request of the Italian national focal point. The aim of this academy was to clarify the role and 
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objectives of the regional drug observatories in Italy. 41 professionals from various regions of 
Italy and six representatives of the Italian national focal point attended the academy. The 
Italian version of the handbook was presented and used as a resource during the training. 
This initiative shows how experience gained by developing the Reitox network can be 
applied or transferred to foster development of national drug observatories elsewhere.
Country overviews containing summaries of the national drug situation were prepared for 
seven former Soviet Union countries: Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, 
Ukraine and Uzbekistan and placed on the EMCDDA’s website.
The Work programme Objective III.1.2. is geared towards ensuring fruitful collaboration 
with European and international partners in the drugs field. In 2010, the EMCDDA 
supported political dialogue by providing up-to-date information on the drugs phenomenon 
in highly relevant policy events, as well as in thematic conferences. Regular contacts and 
coordination meetings with the agency’s institutional partners (European institutions, other 
European agencies, international organisations, other organisations and bodies) occurred 
throughout the year.
The EMCDDA maintained close working relationships with the European Parliament through 
its Committees (mainly the Committee on Civil Liberties, Justice and Home Affairs (LIBE)) for 
content-related aspects, as well as the committees on the budget (COBU) and budgetary 
control (CONT), for budgetary matters (see also the Director’s report on pages 46–47).
Cooperation with the Council of the European Union was mainly ensured through the 
Horizontal Working Party on Drugs (HDG). The HDG meets on a monthly basis. As a 
member, the EMCDDA attended all the HDG meetings that were held in 2010 to which the 
agency contributed with expertise, information and drugs-related analyses. Key EMCDDA 
products, such as reports on the action plan (thematic papers) and the Annual report were 
also presented to the group.
Cooperation with the European Commission was further strengthened in 2010. Coordination 
meetings with DG Justice and DG SANCO occurred throughout the year and the EMCDDA 
was also consulted and involved in meetings linked to the Spanish and the Belgian 
Presidencies of the Council. The collaboration with DG Justice grew in the area of drug 
supply and supply reduction indicators, through the joint organisation of the aforementioned 
First European conference on supply indicators and the provision of input for a paper on 
crime and supply indicators developed by the Commission. A DG Justice representative also 
attended the 10th Annual meeting of the Reitox early warning system network.
In the area of HIV and AIDS, the EMCDDA contributed to the European Commission’s 
session organised at the 2010 International AIDS Conference in Vienna, addressing the 
issue of HIV and drugs policies in Europe, including Eastern Europe and Central Asia. The 
agency also played an active role in the regular EU HIV/AIDS Think tank meetings lead by 
DG SANCO. In 2010, the EMCDDA contributed to two meetings focusing on the new EU 
HIV/AIDS action plan and prison issues. In September 2010, a coordination meeting 
between DG SANCO, DG Justice, the ECDC and the EMCDDA took place in Brussels.
Work with other EU agencies active in the drugs field focused mainly on collaboration with 
the European Centre for Disease Control (ECDC), Europol, the European Medicines Agency 
(EMA) and the European Police College (CEPOL).
In terms of collaboration with the ECDC, a cooperation agreement signed in 2007 involves 
regular data monitoring and exchange of information. This includes the monitoring of the 
seroprevalence of HIV, HCV and HBV among injecting drug users as well as behavioural 
surveillance among this risk group. During 2010 there were a number of initiatives and joint 
projects with the active contribution of both organisations, such as attendance at technical 
meetings as well as the EMCDDA’s input to the report on the implementation of the Dublin 
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Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia or exchange of 
information through the early warning system on DRID. In addition, work started on a joint 
guidance on prevention of infectious diseases among IDUs. The joint EMCDDA and ECDC 
Threat Assessment on Anthrax among drug users was also updated.
Collaboration with Europol takes place within the framework of the Cooperation Agreement 
signed by the two agencies on 19 November 2001. In 2009, a new joint Work programme 
for the period 2009–12 was prepared. As already mentioned, the European Commission 
and the EMCDDA worked with Europol to organise the first European conference on drug 
supply indicators. Regarding the exchange of methodology and strategic information, the 
two organisations give each other mutual support in the preparation of their major 
institutional products and publications. In 2010, Europol provided information and verified 
the relevant texts in the EMCDDA’s Annual report. The EMCDDA and Europol also 
exchanged information on specific substances and when available, on drug seizures, prices 
and purity. As already mentioned, a joint publication on cocaine was also released in 2010.
Concerning support for the implementation of Council Decision 2005/387/JHA, in 2010 a 
regular exchange of information relating to notified new psychoactive substances took place 
with 41 new psychoactive substances reported to both organisations from their respective 
networks – the Reitox national focal points (NFPs) and the Europol National Units (ENUs). 
Furthermore, enhanced exchange of information on new psychoactive substances takes 
place on a daily basis through the EMCDDA’s European Database on New Drugs (EDND), 
to which Europol also has access. Similarly, Europol regularly updates the Europol Synthetic 
Drugs Other Substances Database with shared reports on new psychoactive substances 
seized in the Member States.
A detailed description of all the activities carried out in support of Council Decision 
2005/387/JHA is provided in the EMCDDA–Europol annual report on the implementation of 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of 
new psychoactive substances (see also the section of this report on monitoring new trends).
The cooperation between the EMCDDA and the EMA is also implemented within the 
framework of Council Decision 2005/387/JHA and the EMA’s initiative on cooperation with 
other European Union bodies for early identification and management of potential conflicts 
over scientific opinions. To successfully implement the Council Decision, the EMCDDA and 
the EMA have established a mechanism for the bilateral exchange of information on the 
basis of data available through the EWS, set up by the Decision and the European Union 
pharmacovigilance system. Electronic tools such as existing databases — EudraVigilance 
(EMA) and the European Database on New Drugs (EMCDDA) — are being used to allow a 
rapid and reliable exchange of information. Formalising the scope and nature of the 
information exchange on the misuse of substances with medical value is an area of 
collaboration which is under development. A new working arrangement between the two 
agencies was signed in London on 10 June 2010.
Collaboration with CEPOL also continued in 2010. The EMCDDA provided written input on 
CEPOL´ s Work programme for 2012. Also, as in previous years, the EMCDDA was invited to 
give presentations during CEPOL training seminars. In its turn, CEPOL contributed with a 
presentation to the First European conference on drug supply indicators.
On 1 March 2010, the EMCDDA took over the presidency of the Heads of Communication 
and Information Network (HCIN) of the EU agencies. In preparation for this role, it hosted 
the third annual meeting of the HCIN in Lisbon in February where the network discussed 
upcoming communication priorities and drew up the HCIN Work programme for 2010. 
Highlights of the EMCDDA year-long HCIN mandate included: a major EU agencies’ 
exhibition at the European Parliament (‘EU agencies: the way ahead’); the establishment of 
‘cluster communication’ groups; a meeting of the agencies’ web managers network; a social 
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media strategy; improved HCIN information management tools (online newsletter, document 
repository, media monitoring ‘newsbot’); and participation in the Frankfurt Book Fair and 
annual EU Publications Office meeting for EU agencies. Over the year, the EMCDDA 
established contacts with the European Commission’s Directorate-General for 
Communication (attending meetings of its External Communication Network/ECN) and with 
the European Parliament audiovisual service.
In 2010, the EMCDDA continued to exchange data, methodological information and tools 
with international partners such as: the United Nations Office on Drugs and Crime (UNODC), 
World Health Organization (WHO), Inter-American Drug Abuse Control Commission 
(CICAD), Council of Europe Pompidou Group and World Customs Organization (WCO).
The agency’s work with the UNODC was strengthened in 2010: the EMCDDA provided 
input to the UNODC’s prison situation assessment toolkit and commented on and cross 
checked statistics for Europe in other publications. In addition, the EMCDDA played an 
important role in the revision of the UNODC data-collection tools by active involvement in 
the expert consultation meetings organised in Vienna. The Director and a delegation of key 
staff from the EMCDDA also made a significant contribution to the high level segment of the 
53rd Commission on Narcotic Drugs held in Vienna in March.
Throughout the year, the EMCDDA worked with the UNODC’s regional offices on 
developing capacity and monitoring systems on drugs for non-EU countries. The EMCDDA 
invited all major international and regional organisations, such as: WHO, UNODC, 
Pompidou Group of the Council of Europe, as well as the representatives of the European 
Commission, to attend the ENP seminar in October 2010, to identify possible synergies and 
areas for future joint cooperation.
Other activities with the UN family included the participation in the United Nations 
Interregional Crime and Justice Research Institute and the Italian Department for Anti Drug 
Policies initiative for a Donne Alcol Droga Network (Drugs, Alcohol and Women Network).
In 2010, the EMCDDA also worked closely with WHO. A consultation meeting with the 
representative of the Geneva office took place in Brussels, which concluded that after more 
than 10 years of acting under the current MoU, the instrument should be revised and 
updated according to recent developments in both institutions. This will take place in 2011. 
The cooperation with WHO in 2010 covered: prisons, infectious diseases, quality standards 
of the interventions and monitoring of treatment systems at country level.
In 2010, the EMCDDA took part in the WHO Europe Regional Consultation on the Global 
Health Sector Strategy for HIV/AIDS 2011–15. The EMCDDA is also a member of the 
Advisory Group of the WHO projects on scaling high-quality harm reduction, treatment and 
care for injecting drug users in the European region. There is institutional collaboration on 
mathematical modelling and epidemiological analysis of prevention and treatment effects on 
HIV in IDUs between the EMCDDA, the Dutch National Heath Institute (RIVM) and WHO 
Europe. In 2010, 10 analyses were carried out on different aspects of the epidemiology of 
HIV (and viral hepatitis) in IDUs.
A new Memorandum of Understanding with the Council of Europe’s Pompidou Group was 
signed by the General Secretary of the Council of Europe, Torbjörn Jagland, and the 
EMCDDA Director at the Pompidou Group’s Ministerial Conference in November 2010. The 
EMCDDA took part in meetings of the Pompidou Group’s prevention, treatment, criminal 
justice and ethics platforms, and the airports group, and as observer at Permanent 
Correspondents’ meetings. The EMCDDA was co-organiser of a Pompidou Group MedNet 
seminar on national drug observatories as already mentioned, and participated as trainer in 
a MedNet seminar on treatment demand.
In 2010, the EMCDDA also took part in the joint meeting of the Permanent Technical 
Committee and Enforcement Committee of the World Customs Organization (WCO). 
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Participation at the event strengthened the relations between both organisations and 
provided an opportunity to initiate contacts with WCO regional offices, which resulted in 
exchanges of expertise in the area of new drugs and drug seizures.
The cooperation with CICAD was likewise strengthened in 2010. As already presented, the 
two organisations prepared a handbook on National drug observatories together. This is a 
significant part of a strategic partnership to support the establishment of national monitoring 
capacity in all countries concerned. On 21 September 2010, James Mack, Executive 
Secretary of CICAD, visited the EMCDDA in Lisbon for talks with the EMCDDA’s Director 
(see section on the work of the Director).
Throughout the year, the EMCDDA participated in conferences and expert meetings to 
strengthen institutional relations. Among others, the agency contributed to the setting up of 
the European Society for Prevention Research. Also, the EMCDDA collaborated with the 
Cochrane Drugs and Alcohol Group, was a member of the Programme Committee of the 4th 
annual ISSDP conference and participated in the organisation of the conference on the 
‘Throughcare Services for Prisoners with Problematic Drug Use’ project funded by the 
European Commission (DG Justice). A technical meeting and exchange of expertise between 
the EMCDDA and the Northern Dimension Public Health and Social wellbeing (NDPHS) 
also took place.
Technical assistance to candidate and potential candidate countries
In accordance with its Work programme objectives, the EMCDDA continued to support, 
coordinate and provide technical assistance to candidate and potential candidate 
(stabilisation and association process) countries for their participation in EMCDDA activities 
[Objective III.2.1].
In this context, the overall objective of the IPA (Instrument for Pre-Accession Assistance) 3 
project is to further strengthen the capacity of IPA Beneficiaries (Albania, Bosnia and 
Herzegovina, Croatia, Former Yugoslav Republic of Macedonia, Montenegro, Serbia, 
Turkey, Kosovo under UNSCR 1244/99) to establish, at national level, a drug information 
system compatible with EMCDDA standards. The project has a duration of 23 months (1 
December 2009–30 October 2011) and a total budget of EUR 900 000.
The main accomplishments after the first year of project implementation were the following:
•  the IPA beneficiary national correspondents were appointed;
•  the selection of the Reitox national focal points within the IPA Coaching System was 
made;
•  the project’s kick-off meeting was held and reported on;
•  a final list of 2010 project related national activities was finalised and adopted for each 
IPA beneficiary country;
•  the Reitox academy on EU finances was carried out;
•  the Handbook on building national drug observatories was finalised and published in 
Croatian and Turkish, as well as English, French, Spanish and Italian;
•  a needs assessment report was produced for Kosovo (under UNSCR 1244/99);
•  the process of drafting the first National Action Plan for a Drug Information System 
(NAPDIS) started in some of the countries;
•  information maps and country overviews were updated in most of the IPA beneficiary 
countries;
•  an interim activity report and an interim financial report were prepared for submission to 
the European Commission.
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Chapter 4
Supporting the achievement of results
Communicating the EMCDDA’s findings to external audiences
High-quality, timely and accessible products
In order to publish high-quality and timely products in line with the targets committed to in 
the 2010–12 Work programme [Objective IV.1.1], during the course of the year, 31 
publications and 6 main website areas were published. Each launch was accompanied by 
targeted promotional activities (see Annex 4 for more details).
The publication of the Annual report group of products, and the measures taken to promote 
them, played an important part in the agency’s efforts to ensure the widest dissemination of 
the results of its work. The main launch of the report took place in Lisbon on 10 November. 
The report was also launched in national languages at events in 12 Member States and 
Norway. Published in print and online in 22 languages, the report presented a one-hundred 
page overview and analysis of the drug phenomenon in Europe, based on the most recent 
data. This was supported by a set of other products including the online Statistical bulletin, 
in which much of the statistics collected on drug use and responses to drug use were 
presented in tables and graphics. Also published at the same time were two Selected issues 
on older drug users and problem amphetamine and methamphetamine use in Europe. In 
addition to these publications covering the drug phenomenon at European level, the agency 
published online Country overviews and Reitox national reports.
The EMCDDA’s ability to respond quickly to the needs of policymakers was demonstrated by 
the release, in September 2010, of the Risk assessment report on mephedrone. The 
Monograph entitled Harm reduction: evidence, impacts and challenges, launched in April 
2010 at an international conference in Liverpool, represents an important policy-relevant 
publication delivered on schedule. Three Manuals and Risk assessment guidelines targeted 
more at professionals in the field were also released, encompassing topics as varied as the 
risk assessment of new drugs, infectious disease testing, drug prevention and retail drug 
prices. Joint publications with partner organisations resulted in the Joint handbook on building 
a national drugs observatory in English, French, Spanish, Croatian, Turkish and Italian (Arabic 
and Russian versions will be released in 2011) and a joint publication with Europol on cocaine 
supply in Europe (in English and Spanish). As already mentioned, the EMCDDA also 
published, in English and French, The European Union and the drug phenomenon: frequently 
asked questions with the European Commission. Also published in 2010 was a Selected issue 
on trends in injecting drug use, originally planned for 2009. Continuing on from the successful 
2009 thematic paper Women’s voices: experiences and perceptions of women facing drug 
problems, 2010 saw the publication of a similar thematic paper devoted to children.
Four print and online editions of the quarterly newsletter Drugnet Europe were also 
produced. Summaries of news items and scientific articles by EMCDDA staff were regularly 
included in the newsletter as part of a strategy to promote the agency’s scientific expertise. 
In the course of the year, the EMCDDA entered into an agreement with EBSCO Publishing 
(USA). This grants the publisher the right to include the content of the newsletter in its 
databases, thereby increasing the visibility of the product and the EMCDDA.
In terms of dissemination of the Annual report, of the 26 000 copies printed in all 
languages, 68 % were distributed within one week of the launch. The dissemination of the 
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Annual report and its associated products was enhanced by their availability online on the 
EMCDDA website and on the EU Bookshop site. Data on pdf downloads from the EMCDDA 
website in the two months after the launch underline the demand for multilingual 
publications. Of the almost 20 000 downloads of the 2010 Annual report, non-English 
versions accounted for more than 77 %, which mirrors the non-English proportion of the 
print run. Information on downloads of other EMCDDA products published in 2010 also 
show the importance of this as a means of dissemination. In some of these cases, download 
numbers rival the print runs. For example, more than 5 300 copies of the harm reduction 
Monograph (print run 5 000) were downloaded in the nine months following its launch.
In order to continue improving the relevance and accessibility of products [Objective IV.1.2], 
the ‘Policy, evaluation and content coordination’ unit has been assigned a role in 
coordinating the contents of the agency’s main scientific products that require transversal 
inputs. Various additional measures have also been taken to facilitate the coordination of 
the production process: an improved and more detailed 2010 products website; discussion 
at monthly Editorial Board meetings on overall approach and on individual titles; drawing 
up of more clearly defined workflows and processes per product. The measures taken will 
contribute to the consolidation and better documentation of the production process.
Timeliness was one of the driving principles of the agency’s communications programme. 
The timely publication of the Annual report in all languages relies on the agency and the 
Publications Office achieving a well-coordinated production process. To ensure this, a 
meeting was held between the EMCDDA, the Publications Office and the holder of the 
printing contract in June 2010 to coordinate production.
Throughout the year, there has been an emphasis on ensuring that the Communication unit 
liaises regularly with scientific writers and authors on the progress of their projects. Similarly, 
the introduction of the e-COM tool has centralised ad hoc editing requests and facilitates 
the distribution of work. 317 requests were received and treated in 2010.
In terms of cooperation with subcontractors, ongoing efforts continued in order to improve 
working relations with the Publications Office. A meeting took place in February with the 
Head of Production to plan work for the year and learn more about their framework 
contracts and suppliers.
In order to increase the accessibility of products, the public website was improved. For 
example, improvements made to the online version of the Annual report include a 
redesigned navigation scheme and interactive features. The news section was completely 
redesigned and reorganised. A proposal for reorganising content for the whole website was 
discussed with selected staff members and a proposal was presented to the Editorial Board.
Publications/outputs passing through the Communication unit were launched via press or 
marketing actions. Products were promoted via news materials, the newsletter Drugnet 
Europe, the public website; the EU Bookshop and specialised news services, such as DS 
Daily. EMCDDA products were also displayed at key events (Commission on Narcotic 
Drugs, etc).
In order to increase the practical value of products for targeted end users, two online 
surveys were completed in 2010, one for the website (100 respondents) and a second, 
more specific one during the launch of the Annual report (1 000 visitors). The former helped 
assess the user friendliness of the site and the second helped assess visitor profiles and will 
be used to ensure that the agency’s online content is tailored more appropriately.
Within the same objective to improve the accessibility of products, the EMCDDA continued 
to develop a user-focused policy for multilingualism, including better quality of translation 
whilst rationalising translation costs, where possible. Multilingualism is central to the 
EMCDDA’s endeavours to reach its target audience across all EU Member States and 
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beyond. However, due to financial and production time implications, multilingual publication 
is not a realistic option for most titles. Tracking use of multilingual materials is important for 
making language-policy decisions.
A survey carried out with Reitox focal points on communication and dissemination had one 
section devoted to EMCDDA multilingual materials (i.e. the quality and use made of the 
multilingual materials that the EMCDDA provides). Focal points were also asked to indicate 
the EMCDDA material available only in English that it would be useful to have in translation. 
Several commented that it was only worth translating more if the translations were of higher 
quality. To this end, the first phase of a glossary project to standardise translations of key 
EMCDDA terms was completed in 2010. The complete translated terms are now available to 
a broad audience online via IATE (the European Union terminology database) and are also 
automatically used in their translations carried out via the Translation Centre in Luxembourg, 
hence saving correction time and money whilst ensuring coherence. The focal points 
provided vital input to this process by checking and validating the final translated terms. We 
continue to feedback to the Translation Centre the comments on language quality from the 
focal points in relation to news releases and multilingual summaries of Selected issues and 
policy briefings and also monitor — via download statistics — the use of various language 
versions of our publications.
With the objective of maintaining and further developing an up-to-date and high-quality 
online European reference point on drugs [Objective IV.1.3], existing products were updated 
with new data and data sets for 2010, including the Statistical bulletin and the Country 
overview products (Country situation summaries, data sheets, profiles), and treatment 
overviews.
An in-house study was made of the EMCDDA’s current content management application 
(CMA), analysing how well it fits the agency’s current and future online communication 
needs. Groundwork was prepared for the CMA road map project which will develop a 
strategy for web resources in the future and research possible alternative publishing tools in 
the years to come.
The EMCDDA continued offering up-to-date scientific content through the home page and a 
number of subscriber options, including RSS feeds. As of 2010, two RSS feeds are 
available, one solely for publications and one for all news and publications. The revamped 
news section uses a more streamlined process for publishing news and the ‘web snippets’ 
project was launched to provide regular news items on the home page, drawing on the 
more scientific content from Drugnet Europe. The redesigned area on international partners 
gives a better overview of the EMCDDA’s cooperation with other organisations.
An initial needs analysis was carried out for an ‘Events management tool’, which would 
facilitate the dissemination of information and results of meetings and conferences. This 
project will now be considered in the broader context of planning and monitoring the 
EMCDDA’s work.
In order to improve the scientific quality of products and increase scientific output in journals 
[Objective IV.1.4], several products were reviewed externally: the Harm reduction 
monograph; the Annual report; the Selected issue on injecting and the Joint manual on 
building a national drugs observatory. The Scientific Committee analysed the quality of the 
Annual report in their April meeting and the relevance and quality of Best practice portal 
material in their July meeting. An overall approach for peer review is an ongoing topic of 
discussion in the Editorial Board. Similarly, a strategy on scientific publishing was drafted 
and discussed with the Scientific Committee.
The work to provide reliable and efficient information, library and documentation services 
[Objective IV.1.5] includes four regular information bulletins every two weeks and provides 
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individual staff with the latest information in their subject on a daily basis. New items are 
added to the catalogue at an average of 100 per month. Many of these are electronic 
documents instantly accessible to users through their computer. In addition to proactive 
services, the library responds to enquiries and requests for information using a range of 
databases and external providers. Assistance is provided with literature searching as a 
basis for new projects, and regular updates supplied thereafter.
New materials are evaluated and, where appropriate, added to the catalogue and new 
potential sources of information and document delivery are also examined. In 2010, the 
library opened an account with Subito, a network of German, Swiss and Austrian academic 
libraries, as a source of journal articles which is more cost-effective than the previously used 
British Library. Requests for information are satisfied as quickly as possible, normally within 
two days if not sooner. The book collection is developed from publishers’ catalogues and 
alerts, and in response to user requests. 208 books were added to the collection in 2010.
The library often has the opportunity to help other organisations with requests for 
information on a cooperative basis. In 2011, the EMCDDA will host the Plenary meeting of 
Eurolib, an association of information professionals from all EU institutions and agencies. In 
2010, the EMCDDA librarian was a founding member of a group of small science-based 
libraries within Eurolib dedicated to cooperation and information sharing.
Responding better to differentiated needs
In order to increase responsiveness to covering issues of relevance to target groups 
[Objective IV.1.6], work to tailor products and promotional activities surrounding them for 
our specific target audiences continued. We have been experimenting with new channels, 
e.g. Twitter and uploading publications to specialist databases. A systematic evaluation for 
measuring the relevance of the various channels is planned for 2011.
About 40 international events and conferences were supported with EMCDDA publications 
and brochures assuring that target audiences were reached directly. The national focal point 
survey on communication and dissemination (see above) that we conducted and the ensuing 
workshop have provided us with concrete comments to work on.
New national press contacts are continuously added to the contact management system, 
through which news releases are disseminated to national and Brussels-based press. National 
focal points are encouraged to produce ‘national’ news releases on the Annual report for their 
local journalists. Tailoring in this way will continue to be encouraged as will media briefings 
for national journalists, such as those organised under Reitox media relations academies.
In order to facilitate access to drug-related science and research and promote cooperation 
with the scientific community [Objective IV.1.7], the drug-related research website area was 
kept updated with national and EU research information and overviews and is now 
recognised. The agency promoted and maintained close contacts with DG Research and 
DG Justice on EU-funded projects and national drug-related research. A presentation on 
national and Commission funded research was delivered at the Spanish Presidency’s 
Seminar on EU Research ‘Translating research results into the field of drugs and addictions’.
The EMCDDA was also involved in the drafting of an application for an ERA-NET project on 
illicit drugs, at the request of the leading partners. An application to the Marie Curie Initial 
Training Network (ITN) funding scheme, prepared by a group of European universities, was 
promoted.
The agency participated in the final phase of the setting up of the European Masters on 
Drug and Alcohol Studies, including participation in the pilot session of the Master's course 
whilst a trainee of the European Post-Graduate School in Addiction Research, Technical 
University of Dresden was supported by the agency. To conclude, the EMCDDA is a 
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corporate member of the International Society of Addiction Journal Editors (ISAJE) and 
participated in this organisation’s activities and annual meeting.
Cohesive representation and communication
In order to promote a cohesive and shared approach to representation activities across the 
EMCDDA [Objective IV.1.8], the agency gave brand-related activities a push in 2010 with 
two training courses delivered to newcomers during the year on how to use and maintain 
the EMCDDA’s corporate identity.
The ‘Representing the EMCDDA’ project involved communication and training staff working 
together during the year to analyse how to advance in the light of an upcoming framework 
contract for training (to run from 2011–13). The feeling is that ‘Representing the EMCDDA’ is 
a task for all staff members in different ways and that all staff should be given the 
opportunity to participate in the course as a corporate exercise over a three-year period. A 
concept paper and terms of reference for this action were submitted at the end of the year 
for inclusion in the comprehensive training tender.
In terms of corporate stationery, a tender resulted in a four-year framework contract (DPI 
Cromotipo, Portugal) being drawn up at the end of 2010, to run from January 2011. 
Similarly, terms of reference to refresh the EMCDDA brand will be drawn up in 2011. 
Branding the new EMCDDA premises and equipping common areas for promotional events 
remained on the agenda in 2010.
The agency’s Imagebank was launched and populated with more than 500 graphical 
elements by the end of 2010. The logos, graphics and photos provided support staff in 
preparing presentations and reports and assure the corporate use of images.
Work was also carried out in 2010 in relation to the branding of two EMCDDA conferences 
in October. This entailed liaising with designers in the conception of the conference brand 
and accompanying production of conference materials. Various promotional items were 
produced in the course of the year to support these events as well as activities of the Heads 
of Communication and Information Network (HCIN) of the EU agencies.
‘EMCDDA, your reference point on drugs in Europe’
In order to enhance the EMCDDA’s reputation and recognition as the European central 
reference point and authoritative information source in the drugs field [Objective IV.1.9], the 
EMCDDA invests in nurturing partnerships with journalists via press office activities and 
press events. The media are a major conduit to raising awareness and reaching our target 
audiences. In January 2010, the EMCDDA held an informal briefing for the Association of 
Foreign Press in Portugal on work in the pipeline for 2010. During the Annual report launch 
in November, some 25 journalists were invited from Member States to the EMCDDA to 
cover this event, along with a small selection of the Brussels press corps.
Particular attention was paid in 2010 to updating contacts of the most prestigious peer-
reviewed scientific journals as well as the Brussels-based media. Throughout the year, press 
office activities led to collaboration with various entities across Europe on a variety of 
projects, including documentaries or other visual productions.
Regular news items were disseminated throughout the year, resulting in a total of: 14 news 
releases (12 in 2009), 9 fact sheets (6 in 2009) and a regular flow of ‘web snippets’ on the 
homepage. Additional press materials were produced as part of the Annual report 
promotional strategy. As already mentioned, regular use of Twitter also became part of the 
press workflow in 2010.
Together these channels marked the launch of a steady stream of EMCDDA products and 
services; high-level visits (e.g. Commissioner Dalli, Europol Director); institutional news 
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(Memoranda of Understanding); special occasions (two EMCDDA conferences) and 
International days (International children’s day, 1 June; International day against drug abuse 
and illicit trafficking, 26 June).
Considerable investment was made in 2010 in assessing the impact of the EMCDDA’s 
media work, particularly regarding the launch of the Annual report. Two calls for tender 
resulted in two media monitoring contracts around the Annual report launch in the autumn. 
These analysed coverage worldwide (Kantar, UK) and in Portugal (Cision, Portugal). Kantar 
Media carried out a media monitoring analysis on the launch of the Annual report, covering 
the 27 EU Member States, Norway (EMCDDA member) and Croatia and Turkey (candidate 
countries). Also included in the analysis were international media, ‘Europa’ media (Brussels- 
focused) and the communication channels of the EU institutions. A total of 2 192 items of 
coverage were recorded (up from 1 508 in 2009), with data being sourced from 52 
countries in total.
The analysis also includes Advertising Value Equivalent (AVE) and Opportunity To See (OTS) 
figures relating to the coverage. These PR industry standard measurements give an 
approximate indication of the benefit to the EMCDDA from the media coverage. The total 
AVE for all coverage was EUR 5 324 236 and the total OTS was EUR 278 855 530.
A communication performance analysis regarding the launch of the report specifically in the 
Portuguese media was also commissioned for the period 8 November to 14 December 
(Cision). This monitoring report (covering the written press, TV, radio and online news) 
revealed the publication of 130 news items, reaching in the region of 12 million readers. 
The estimated AVE of this coverage was EUR 413 027. The majority of the articles (97 %) 
focused on the launch of the report and its key findings.
The EMCDDA continued its monthly reporting cycle on press requests and coverage via 
press reviews. Press reviews were also compiled in the wake of key events. Incoming press 
services were analysed for relevant articles which were made available to staff on the 
Internet press area. In the course of the year, the EMCDDA press office received around 
250 requests from the media, averaging around 20 per month.
Governance, management and networks
Internal organisation
The Work programme for 2010 set the objective of pursuing organisational and scientific 
management solutions that improve scientific coordination, organisational effectiveness and 
efficiency [Objective IV.2.1]. In particular, one focus was on organisational management 
solutions that improve organisational effectiveness. To this end, the EMCDDA undertook an 
internal exercise of reviewing its structures, processes and behaviours. This was done, inter 
alia, to accommodate and adapt to the evolution and development of the agency’s tasks 
according to its priority areas set out in the recast of its founding regulation and according 
to the new EU drugs strategies and action plans.
The purpose of the whole exercise was to assess if, and how, the EMCDDA could improve 
its organisational effectiveness, as well as the overall quality, rigour and usefulness of the 
agency’s work and outputs.
The process chosen involved an internal reflection open to all staff members, addressing 
issues such as the inner structures of the organisation, but also working processes and 
management procedures, plus internal working behaviours as well as relations with third 
parties. The main outcome of this exercise was the adoption by the Director of a new unit-
based organisational structure, which was endorsed by the Management Board. This 
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restructuring was also strongly supported by the agency’s Scientific Committee, which 
welcomed in particular the focus it gives to the agency’s scientific endeavours.
Hence, the three pre-existing scientific units (EPI, RES and SCD) were transformed into one 
Scientific division with four units: Interventions, best practice and scientific partners (IBS); 
Supply reduction and new trends (SAT); Prevalence, consequences and data management 
(EPI); Policy, evaluation and content coordination (POL) (see new organisational chart in 
Annex 2). This Scientific division, headed and supervised by a Scientific Director reporting 
to the agency’s Director, is formally responsible for all content-related issues, for ensuring 
coordination and management of the work of the four scientific units proposed, for ensuring 
the coordination between these and the other EMCDDA transversal operational units (Reitox 
and International Cooperation unit and Communication unit), and finally for inter-institutional 
coordination at EU level.
The creation of a single Scientific division will allow for more consistent and coherent 
decisions across the scientific units in terms of activities and outputs.
With the exception of the Communication unit that absorbed the Documentation service, the 
other units remained unchanged.
Finally, the agency refreshed the mission statement of each of the its units in order to give 
more consistency and focus to the work of each of them.
The revision was implemented within the limits of the EMCDDA establishment and staff 
policy plans and budget currently in force, since the new posts created were filled by 
internal transfer of existing posts.
Once the re-organisation of the structure was completed, the agency updated its 
organisational chart, revised the decisions on delegation of the appointing authority’s 
powers and reassignment of the concerned staff, carried out internal selection procedures to 
fill the posts of Scientific Director and Heads of the new units and finally, appointed the 
successful applicants.
Director — Main activities
As every year, the work of the Director was largely oriented towards enhancing the 
credibility of the work of the agency and building and improving partnerships.
EU institutions
As in recent years, the Director presented the Annual report to the European Parliament 
Committee on Civil Liberties, Justice and Home Affairs (LIBE Committee). During the year, Mr 
Götz had meetings with several members of the LIBE Committee namely with its Chair and 
Vice-chair Mr Juan Fernando López Aguilar and Mr Salvatore Iacolino, respectively.
As regards relations with the Council of the European Union, the key event was the 
presentation of the 2010 Annual report to Ministers at the Justice and Home Affairs Council on 
9 November prior to its public launch and at the behest of the Belgian presidency. As a 
follow up to the launch of the 2010 Annual report, the Director attended the Horizontal Drugs 
Group on 21 December in Brussels. Also in the framework of the Belgium Presidency, Mr Götz 
participated on 16 November in the National Drug Coordinators meeting in Brussels, where 
he gave an overview on comprehensive and integrated drug policies in Europe.
Key events in relations with the European Commission were the meeting with Ms Cecilia 
Malmström, Commissioner for Home Affairs, on 21 October in Brussels and the visit to the 
EMCDDA of John Dalli, Health and Consumer Policy Commissioner on 8 November 2010. 
Furthermore, Mr Götz met the Directors-General for Justice and Home Affairs.
Chapter	4
47
EU agencies
During 2010, Mr Götz attended the two Heads of EU Agencies meetings and addressed the 
annual meeting of the EU agencies’ Heads of Communication and Information Network 
(HCIN) organised by the EMCDDA from 8 to 9 February.
The Director also welcomed in Lisbon Mr Rob Wainwright, Director of Europol, on 25 
March and a delegation of the European Centre for Disease Prevention and Control (ECDC) 
on 11 and 12 February. These visits helped exchange information on ongoing projects that 
are of interest to both agencies, strengthen the existing collaboration and agree on a formal 
cooperation mechanism.
Relations with EU Member States
Due to the agency’s location in Lisbon, relations with the Portuguese authorities are 
particularly important. Visits to the EMCDDA in 2010 included the Secretary of State for 
Health, Dr Manuel Pizarro, the Secretary of State for European Affairs, Mr Pedro Lourtie, 
and MP Maria Antónia Almeida Santos, representing the Chair of the Health Committee of 
the Portuguese Parliament. Furthermore, on 21 December, the Director presented the Annual 
report to the Portuguese Parliament, together with the presentation of the Annual report on 
the drug situation in Portugal by the Portuguese national drugs coordinator. Finally, on 24 
June, the EMCDDA hosted, as usual, a reception to commemorate the International Day 
against Drug Abuse and Illicit Trafficking of 26 June.
The Director also participated in the press conference on the occasion of the launch of the 
German report on the drug situation together with the German Drug Commissioner Ms 
Mechthild Dyckmans.
Relations with non-EU countries
Following the mandate given by the EMCDDA Management Board, the Director signed on 
28 January in Kiev, a Memorandum of Understanding between the EMCDDA and the 
Ukrainian Minister of Health, Mr Vasyl Mykhailovych Knyazevich.
On 29 September, the Director welcomed a high-level delegation from the United States of 
America headed by Mr Gil Kerlikowske, Director of the Office of National Drug Control 
Policy (ONDCP). Prior to this visit, on 9 June the Director also welcomed a delegation of the 
United States of America Joint Interagency Task Force South, chaired by Rear Admiral 
Daniel B. Lloyd.
Other organisations and bodies
Mr Götz attended the fifty-third session of the Commission on Narcotic Drugs, in Vienna — 
an annual event organised by the United Nations Office on Drugs and Crime.
With regards to cooperation with the Pompidou Group, the Director attended the Inter-
Ministerial Conference in Strasbourg held on 3 November. In the margins of that meeting, 
the Director and Mr Thorbjorn Jagland, Secretary-General of the Council of Europe, signed 
a Memorandum of Understanding between the two organisations. The Director also attented 
its IVth Inter-Agency Group meeting on 19 January in Gdansk.
Mr James Mack, Executive Secretary of the Inter-American Drug Abuse Control Commission 
(CICAD), visited the EMCDDA headquarters on 21 September 2010. On this occasion a 
joint Work programme for 2011–13 was signed. Within the framework of the cooperation 
with CICAD, the Director also attended and addressed the opening session of the EU–LAC 
Drug Treatment City Partnership Forum in Coimbra.
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External visitors
During 2010, EMCDDA staff successfully coordinated and organised 29 external visits. Almost half 
of these visits were to improve visitors’ understanding of the mandate and activities of the EMCDDA, 
the other half focused on discussions about possible cooperation and exchange of technical 
knowledge in specific scientific areas.
There were six visits of Ambassadors to Portugal (Czech Republic, Denmark, France, Greece, 
Morocco, Netherlands). There was also a specific visit, jointly organised with our sister agency the 
European Maritime Safety Agency of all the Ambassadors to Portugal from the EU Member States, 
Norway and candidate countries, and another of the Ambassadors to the CPLP (Community of the 
Portuguese speaking countries). There were 14 national country representations from Australia, 
Brazil, France, Greece, Ireland, Japan, Norway and the USA. A delegation including members of 
Parliaments from Asian countries (Burma, Cambodia, Laos, Thailand and Vietnam) also visited the 
agency. Finally, the agency played host to a delegation from MAOC-N (the Maritime Analysis and 
Operation Centre — Narcotics) an inter-governmental working group or taskforce comprising seven 
EU Member States set up to tackle maritime drug smuggling in Europe.
Statutory bodies
To provide support to EMCDDA statutory bodies to facilitate strategic decision-making and 
scientific advice regarding quality of EMCDDA work was Objective IV.2.2 for 2010.
Management Board — main decisions
The Management Board met twice during the year, on 1–2 July and 9 December. The July 
meeting was the first under the Chairmanship of Dr João Goulão, Portuguese national drug 
coordinator and Head of the Institute for Drugs and Drug Addiction.
At its July meeting, the Board:
•	 	gave a favourable opinion on the final accounts of the EMCDDA for 2009
•	 	approved the revision of the organisational structure of the EMCDDA’s scientific area 
(already presented) to improve work and internal collaboration, in accordance with 
Article 11 para 3 (g) of the recast Regulation
•	 	adopted measures, including discontinuing the translation of working documents for its 
meetings into English, French and German, in order to streamline meetings of statutory 
bodies and save money
•	 	agreed with a new Memorandum of Understanding between the Co-operation Group to 
Combat Drug Abuse and Illicit Trafficking in Drugs of the Council of Europe (Pompidou 
Group) and the EMCDDA.
The EMCDDA’s 2011 budget and Work programme were key points on the agenda at the 
42nd meeting, which took place on 9 December. Here, the Management Board:
•	 	gave its final seal of approval on the 2011 draft Work programme. This was generally 
considered as comprehensive and ambitious, was very well received and adopted at 
unanimity by the members of the Management Board
•	 	adopted the 2011 budget of EUR 15 909 938, on the basis of an EC subsidy of 
EUR 15 400 000. This covers 27 Member States, Norway and Turkey
•	 	further adopted a preliminary draft budget of EUR 16 419 486 for 2012 (27 Member 
States, Norway, Turkey and Croatia) on the basis of an EC subsidy of EUR 15 750 000
•	 	elected Mr Mogens Jørgensen (Denmark) and Ms Minerva-Melponi Malliori (Greece) as 
members of the Executive Committee
•	 	approved the agency’s staff policy plan for 2012–14.
Chapter	4
49
Meetings of EMCDDA Management Board
1–2 July Lisbon 41st Management Board meeting
9 December Lisbon 42nd Management Board meeting
Executive Committee — main decisions
In 2010, the Executive Committee met four times (5 May, 30 June, 6 October and 8 
December) in Lisbon.
At its meeting of 5 May, the Executive Committee:
•	 	commented on the draft documents of the subsequent Management Board meeting in July
•	 	agreed with the draft working arrangement between the EMCDDA and the European 
Medicines Agency (EMA), which was adopted by written procedure by the Management 
Board on 26 May 2010 and signed by the Directors of both agencies on 10 June 2010 
at the EMA headquarters in London
•	 	adopted, on behalf of the Management Board, the EMCDDA rules applicable to national 
seconded experts from other Member States to be employed on secondment at the 
agency, built on the ones applied by the European Commission.
On 30 June, the Executive Committee:
•	 	prepared the Management Board meeting of 1–2 July 2010
•	 	adopted EMCDDA implementing rules on the attestation procedure for officials on behalf 
of the Management Board.
Upon recommendation of the Budget Committee, the Executive Committee decided at the 
meeting of 6 October to launch a written procedure for the adoption of the amendment 
No 2 of the 2010 budget by the Management Board. The Executive Committee further 
commented on the draft agenda and draft documents for the upcoming Management Board 
meeting in December.
On 8 December, the Executive Committee prepared the Management Board meeting of 9 
December. The Chair also informed the Committee members about the outcome of a 
meeting he held with the Vice-Chair of the Scientific Committee, the Spokesperson of the 
national focal points, the EMCDDA Director and the Scientific Director, before the Executive 
Committee meeting, about the challenges the EMCDDA faces in 2011.
Meetings of EMCDDA Executive Committee
5 May Lisbon Meeting of the Executive Committee
30 June Lisbon Meeting of the Executive Committee
6 October Lisbon Meeting of the Executive Committee
8 December Lisbon Meeting of the Executive Committee
Scientific Committee
The Scientific Committee completed its first three-year mandate in the new composition 
called for by the EMCDDA Regulation recast, with 15 members and one member from 
Norway as observer, selected on the basis of their scientific excellence.
The Scientific Committee convened for regular meetings twice during 2010, on 16 July and 
on 15–16 November. The July meeting was combined with a risk assessment meeting on 
mephredrone in accordance with Article 6 of Council Decision 2005/387/JHA. In the 
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framework of the evaluation of the Council Decision, the EMCDDA Director asked for the 
Committee’s opinion on the scientific aspects of the risk assessment.
In the framework of the Swedish Presidency Council Conclusion on strengthening EU 
research capacity on illicit drugs (8), the Scientific Committee contributed to the annual 
dialogue on drug-related research in the Horizontal Drugs Group with indications for 
priorities in drug-related research at European level.
Scientific evidence and best practice were one focus of the Scientific Committee’s work in 
2010. Members gave input to the conceptualisation of different modules and contributed to 
the validation of the Best practice portal. The Committee was represented on the steering 
committee of the EQUS (Development of an EU framework for minimum quality standards 
and benchmarks in drug demand reduction) project.
The Scientific Committee reviewed the 2010 Annual report and Selected issues, as well as 
other publications and scientific papers. It gave input and advice for the Insights series on 
treatment modalities. Members participated in expert group meetings and informal 
discussion fora. The Committee presented the session ‘Addiction treatment – the limits of 
research findings’ at the ESOF (European Science Open Forum) Conference in Torino in July.
The Scientific Committee issued a favourable formal opinion on the EMCDDA Work 
programme for 2011.
Meetings of the Scientific Committee
16 July Lisbon 32nd Scientific Committee meeting
15–16 November Lisbon 33rd Scientific Committee meeting
Reitox network
In 2010, the agency set out to assure the strategic development of the Reitox network, its 
visibility and management with a view to ensuring high-quality EMCDDA products 
[Objective IV.2.3]. Progress focused on grant management, and on the direct support 
provided to the national focal points. With a view to improving internal processes at the 
level of the Reitox and International Cooperation Unit and to support sound management 
decisions, dedicated software was developed by an external contractor. Intermediate 
versions of the software were piloted and an initial training session was organised for the 
Reitox and International Cooperation Unit staff. The final version of the software will be 
implemented in 2011.
Following the adoption of the vision and mission statements of the Reitox network by the 
heads of the national focal points in November 2009, further reflection took place 
throughout 2010 with regard to the drafting and implementation of a Reitox development 
strategy. The main goals of the strategy are to clearly define the perceived value and the 
key role that the Reitox network plays at both national and European levels.
The discussions in this area provided the first basis for the definition of objectives and 
activities for the Reitox network for 2010 and 2011. Further discussions will take place in 
2011, with a view to have a final Reitox development strategy, to be adopted by the end of 
2011.
The EMCDDA organised two Reitox Heads of national focal points (HFP) meetings in 2010, 
on 26–28 May and 24–26 November.
(8)  Council of the European Union, ‘Council conclusions on strengthening EU research capacity on illicit 
drugs’, CORDROGUE 78, 17177/09, Brussels, 7 December 2009. 
Chapter	4
51
Meetings of the Reitox network
26–28 May Lisbon 42nd Reitox meeting of heads of focal points
24–26 November Lisbon 43rd Reitox meeting of heads of focal points
Administration and supporting core business
Human Resources
The objective in terms of human resources set for 2010 was to further develop the 
implementation and monitoring policies, procedures and tools for effective management of 
the EMCDDA s´ staff [Objective IV.3.1].
In order to finalise the Human Resources (HR) legal framework, implementing rules were 
drafted and presented to the EC for agreement under Article 110 of the Staff Regulations 
(i.e. performance appraisal of the EMCDDA Director, temporary occupation of managerial 
positions, middle management). Other rules were drafted on professional 
underperformance, harassment, reclassification of contract staff and attestation of temporary 
agents. They will be submitted for consultation and agreement during 2011. With the aim of 
improving the existing policy on flexitime, some amendments to the current rules and 
procedures were proposed to the EMCDDA Director. Other HR policies are permanently 
monitored and periodical feedback on implementation is provided to the management. 
Depending on the promptness of the EC in granting its agreement, the full set of rules and 
processes to implement Staff Regulations should be in place in 2011.
For improving human resources management and enhancing scientific excellence and 
recognition of the EMCDDA s´ staff [Objective IV.3.2], the EMCDDA’s training capacity and 
offer were developed. Over 20 training activities took place in 2010 as well as other 
professional support actions. As part of its permanent training offer, the EMCDDA provided 
language courses in Portuguese, English, French and German, at various levels. To complete 
these measures, further initiatives were identified to improve the recognition of staff 
capacities and favour opportunities for professional and career development. The 
implementation of these initiatives is planned for 2011.
Financial management
In 2010, the agency set out to assure and further enhance appropriate processes and 
procedures for efficient and effective financial management and control [Objective IV.3.3]. 
Financial and contractual assistance (9) and training on financial management and 
procurement was provided to the EMCDDA’s relevant staff by means of five training sessions 
concerning different budget and financial operations and processes (37 staff members). The 
daily management of contracts and budgetary transactions, including ex-ante verification 
and bank transfers, represented a total of 3 145 operations (10).
A workshop was held for internal users of the ABAC Data Warehouse (29 staff members) to 
ensure full and better use of the concerned tools. Training on the ICT-based application 
‘ABAC Contracts’ (13 participants) and coaching for financial and accounting team staff 
(seven participants) was also provided. Furthermore, the reporting capacity of ‘ABAC 
 (9)  38 calls for tender (3 Open procedures (OJ), 17 Negotiated procedures with at least 3 candidates, 7 
Negotiated procedures with at least 5 candidates, 11 Negotiated procedures — disp. Art. 126).
(10)  3 145 operations (2 509 payment orders/bank transfers, 86 recovery orders as well as mission requests, 
creation of legal entities and bank accounting files).
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Contracts’ was used to cope with the requests for information made by the Court of 
Auditors.
The EMCDDA’s ABM/ABB (Activity-based management and Activity-based budgeting) and 
cost-based accounting system were (re)designed to fit with the re-organisation of the 
EMCDDA’s working structure and management of activities.
Accounting
In order to ensure that accounting data and related information used for preparing 
EMCDDA accounts and financial statements are accurate and timely [Objective IV.3.4], 
ABAC-SAP accounting tools, along with Data Warehouse and SAP reporting tools, were 
further developed in 2010.
A better coordination between all persons involved in the financial management process 
was achieved, namely to improve the accuracy of the EMCDDA's financial statements. In 
this context clearer and more structured instructions and procedures were put in place for 
the definition of appropriations to be carried forward.
Planning and reporting
To coordinate and administer effectively the planning, reporting and monitoring processes 
of the EMCDDA’s work [Objective IV.3.5], the 2009 General report of activities (GRA) was 
prepared and transmitted to the European Parliament, the Council of the European Union, 
the European Commission, and the Court of Auditors on 14 June 2010.
In terms of planning, core to the work in 2010 was the preparation of the 2011 Work 
programme involving all units. The first draft of the Work programme was sent to the 
Executive Committee in September for comments, as well as the European Commission, 
the Reitox network and the Scientific Committee, for formal consultation. The second draft 
which includes comments from the former was approved by the Management Board in 
December.
Mid-year monitoring of the implementation of the 2010 Work programme was conducted in 
June. The reporting tool endorsed by the Management Board in 2009 for monitoring the 
three-year strategy and Work programme was used to collect information on progress.
The process of implementing a performance monitoring system will be further developed in 
2011. A new staff member was recruited in 2010 and they will be fully dedicated to 
improving the EMCDDA s´ strategic planning, performance monitoring and reporting 
activities.
Infrastructure and logistics
To develop safety at work, sound environmental management and security in the buildings, 
including reducing utility costs and promoting use of renewable energy [Objective IV.3.6], a 
physical verification and review of the EMCDDA assets was carried out, namely on office 
furniture in the headquarters.
The Interagency Greening Network Meeting organised by the EMCDDA took place in 
Parma in October 2010.
An assessment of possible renewable energy sources for the EMCDDA headquarters was 
prepared. Several energy preservation measures were put in place namely to rationalise the 
use of air conditioning and lighting systems and economies were already noted in one of 
the compound’s communal buildings.
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A security risk assessment was conducted in August 2010 and as a follow-up all new staff 
received a security briefing in the second half of 2010. No accidents were reported on the 
premises in 2010.
In order to provide a suitable work environment and related services, and improve efficiency 
and effectiveness through promoting a customer-oriented approach [Objective IV.3.7], each 
staff member was guaranteed the EU standard of quality in terms of their work environment.
The EMCDDA policy for the management and archiving of documents was reviewed in 
order to follow up to recommendations expressed by the European Data Protection 
Supervisor (EDPS).
ICT
The Work programme defines Objective IV.3.8. as: ‘to ensure successful and efficient 
delivery of results through quality, cost-effective and timely ICT support services, 
infrastructure and solutions’. The activities needed to guarantee the support to the pillar work 
processes of the agency including data collection, data analysis and the development and 
dissemination of the EMCDDA products, were successfully executed, through the provision 
and effective running of the main supporting applications (Fonte, Analytical database and 
Web content management). Upgrades needed were also made as required. In this respect, 
ICT also provided strategic input to different roadmaps being developed for the evolution of 
these applications and services, to ensure they include new business requirements.
The ICT 2010–12 strategy includes several overarching programmes pertaining to the 
reviewing of resource utilisation, service capacity development and overall governance. In 
2010, a baseline was created in the area of Service Management (based on the ISO 
20000 standard) and a partial version of a Services catalogue developed.
In the area of planning and project management, an initial catalogue on running and 
planned ICT projects was developed and kept up to date on the Intranet, to be discussed at 
management meetings. This initiative is expected to develop and provide a closer steering 
of the ICT function by the EMCDDA management.
The ICT unit ran 44 projects in 2010. These have ranged from data collection, data 
analysis, and information dissemination to corporate application suites, sectoral application 
suites, ICT services management and governance. Many of these projects are not officially 
closed, although most of them have produced several outputs and reached major 
milestones. All products and deadlines were met in a timely fashion.
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Chapter 1
Characteristics and nature of EMCDDA management 
and internal control systems
In accordance with the Financial Regulation applicable to the EMCDDA, which transposes 
integrally the text of the Framework Financial Regulation (EC, Euratom) No 2343/2002 (11), 
the EMCDDA has set its internal procedures for budget execution and internal control, while 
defining and implementing a partially decentralised management model.
As a consequence, both operational and financial decisions required for the implementation 
of the EMCDDA’s Work programme and budget have been delegated to the Heads of unit. 
The Administration unit provides support to managers for budgetary and financial 
management and execution, as well as for overall internal planning and monitoring.
These procedures have been codified and all of the EMCDDA’s Heads of unit/deputy 
authorised officers have received specific training and information on their role, duties and 
liability, in accordance with the provisions of the financial and staff regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
•	 	Project manager: initiative and operational input for the administrative and financial 
operations in relation to project implementation (technical specifications for tendering 
procedures, cost estimate, ‘certified correct’ for payments)
•	 	Financial management team: financial and contractual support officers help prepare the 
administrative and contracting supporting documents with the input of the project 
manager concerned
•	 	Budget planning and monitoring team: checks consistency with Work programme and 
budget allocations
•	 	Financial management team: ABAC initiating officers carry-out operations in the 
EMCDDA’s ABAC electronic management and accounting system, prior to the decision of 
the authorising officer
•	 	Directorate: the verifying officer carries-out ex ante checks
•	 	Head of unit: gives authorisation of budgetary and legal operations, acting as deputy 
authorising officer by delegation (from the Director as EMCDDA authorising officer) for 
the execution of the tasks/activities of his/her unit, within the limits of the adopted 
EMCDDA annual Work programme and budget
•	 	Accountant: makes the required financial transactions.
The procedures presented above are consistent with the EMCDDA’s project-based working 
methods aimed at integrating activities and resources management, in accordance with the 
activity-based management/activity-based budgeting principles. In this context, the 
EMCDDA has established procedures for planning, monitoring and reporting, with a clear 
indication of the actors involved, their roles and responsibilities.
Following the adoption of the new ‘Operating framework for the Reitox system’ in January 
2003, a new grant agreement model has been introduced for the annual co-financing of 
activities by the Reitox national focal points. This agreement requires that an external audit 
be carried out each year by an independent body or expert in order to certify that the 
financial documents submitted to the EMCDDA comply with the financial provisions of the 
(11) As last amended by Commission Regulation (EC, Euratom) No 652/2008.
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agreement, that the costs declared are the actual costs, and that all receipts have been 
declared.
The EMCDDA is currently subject to the following checks and controls:
•	 	External audit by the European Court of Auditors (twice a year)
•	 	External audit for specific projects (CARDS, IPA, etc.)
•	 	Discharge by the European Parliament (once a year)
•	 	Internal audit by the European Commission’s Internal Audit Service (once a year)
•	 	Opinion of the European Commission’s services on the agency’s staff policy plan (once a 
year)
•	 	External periodical evaluation (set as every six years in the EMCDDA founding regulation)
•	 	Agreement by the European Commission on implementing rules to Staff regulations (for 
each rule)
•	 	Consent by the European Commission on possible deviation of EMCDDA Financial 
Regulation from the European Commission’s Framework Financial Regulation for 
decentralised agencies
•	 	The European Data Protection Supervisor for compliance with Regulation 
(EC) No 45/2001 (by prior notification and upon complaint)
•	 	The European Anti-Fraud Office (upon complaint)
•	 	The Ombudsman (upon complaint)
•	 	Civil Service Tribunal — Court of First Instance — European Court of Justice (upon 
complaint).
2
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Chapter 2
Assessment and improvement of management and 
internal control systems
Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational 
and technical units)
Operational initiative/input and operational and financial 
decisions by delegation in order to implement the Work 
programme (WP) and budget
Central level (Directorate and 
Administration unit)
Coordination and management of executive planning, 
monitoring, reporting and assessment of the implementation of 
the WP and budget.
Administrative and financial support, management and control 
of implementation
Key actors and processes for the execution of the EMCDDA Work programme 
and budget
Level of operations Actors Role/operations
Decentralised level 
(operational and  
technical units)
Project manager and 
Head of unit 
concerned 
Initiative and operational input for the 
operations required to implement projects 
Central level  
(Administration unit)
Budget planning 
and monitoring team
Checks consistence of operations with 
adopted WP and budget. Budgetary 
appropriations to be committed are set aside
Human resources 
management team
Defines rights and checks compliance with 
staff regulations for staff-related management 
and expenditure 
Financial 
management team
Prepares the required administrative and 
legal supporting documents and controls 
compliance with applicable regulations. 
Processes the required ABAC operations
Central level (Directorate) Verifying officer Ex ante verification
Decentralised level 
(operational and  
technical units)
Head of unit/ 
deputy authorising 
officer 
Authorise budgetary and legal commitments 
and payments
Central level  
(Administration unit)
Accounting officer Executes and records payments and recovery 
orders
In 2010, following up on observations and recommendations expressed by the European 
Court of Auditors and the EU Budget Authority and audits by the Internal Audit Service of 
the European Commission (IAS), the EMCDDA implemented some measures to improve its 
management and internal control systems as follows:
Measures taken in the light of the observations and comments accompanying the Decision 
on the discharge for 2008
Performance
The EMCDDA’s annual budget and Work programme give information on the allocation of 
resources required for the implementation of planned activities, in accordance with the 
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principles of activity-based management. Pursuant to the same principles, the EMCDDA’s 
General report of activities presents the actual use of these resources.
In 2010, as part of its development of an integrated system for activity-based management 
and budgeting, the EMCDDA started to set up an analytical accounting system. For this 
purpose, it took into account the technical options and tools provided by the ABAC system.
Furthermore, following the appointment of a fully-dedicated extra member of staff (AD 
temporary agent), the EMCDDA increased its capacity for further improving its planning 
and monitoring system, with special focus on the development of suitable performance 
indicators.
Internal Audit
The EMCDDA has followed up the IAS’ recommendations referred to in the aforementioned 
discharge Decision, in particular, concerning the needs created by the agency’s move to 
new premises.
Cash management
In accordance with the relevant financial provisions and pursuant to a Memorandum 
concluded in 2010 with the European Commission services concerned, the EMCDDA’s cash 
flow management now relies on a structured and detailed annual forecast of its cash needs. 
This should further enhance the efficiency and effectiveness of this process.
Measures taken in the light of the observations and recommendations expressed by the 
Internal Audit Service of the European Commission (IAS)
The IAS conducted an audit on the management of outputs for external communication in 
2010. This gave rise to the following main recommendations:
•	 	to provide a more explicit link between the EMCDDA Communication strategy and the 
annual and multi-annual Work programmes, having in view the needs of target groups;
•	 	to set up in future Work programmes measurable objectives for communication activities, 
together with relevant performance indicators;
•	 	to consolidate the procedures used for the production of external outputs, notably by 
identifying the key actors and risks involved at the different steps of the process; and
•	 	to better document workflows for the publication cycle, notably at the authorisation 
phase.
An action plan aimed at dealing with these recommendations was approved by the 
EMCDDA Management Board on 9 December 2010 and promptly sent to the IAS Director-
General.
Moreover, in 2010 IAS promoted an Information Technology (IT) Risk Self-Assessment and 
Maturity Self-Evaluation in the EMCDDA. The main objectives of this initiative were to 
identify and evaluate key IT risks and the level of maturity of the IT function in the EMCDDA. 
The results of this exercise were substantially in line with the findings that had been reflected 
in the EMCDDA’s risk register, as provided to the IAS’ auditors at the moment of their audit 
mission.
Measures taken in order to improve the risk assessment and management system as a 
whole
A comprehensive methodology for the carrying out of risk identification and assessment as 
a tool for improving risk management in the EMCDDA was defined and approved in 
February 2010. The responsibilities of all actors involved in the process have been duly 
clarified, notably as regards the methodology for assessing risks, the selection of risk 
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responses and the definition of action plans and mitigating measures aimed at dealing with 
internal control weaknesses and identified external risks. As a result of this initiative, a 
central risk register has been set up, in line with both the recommendations issued earlier by 
the IAS and the requirements laid down in the EMCDDA Internal Control Standards, as 
formally adopted by the Management Board in its meeting of July 2010.
Measures taken in the light of the observations and recommendations expressed by the 
European Court of Auditors
Budget — Carry-forwards
The following measures have been taken by the EMCDDA to further develop the analysis of 
the actual needs for budget carry-forwards and to further reduce, as much as possible, the 
volume of appropriations carried forward:
•	 	five training sessions concerning budget operations and procurement processes have 
been held for the EMCDDA’s different financial and operational actors. These focused on 
carry-forward operations and on the monitoring of planned activities, with special 
attention paid to activities and expenditure under Title II of the EMCDDA budget;
•	 	clearer and more structured instructions and procedures (guidelines and a specific Excel-
based tool) have been put in place for the analysis and prevention of potential carry-
forwards (both at the level of the concerned deputy authorising officers and of the officers 
in charge of budget monitoring and accounting);
•	 	the tendering processes aimed at implementing the annual WP/budget have been 
anticipated as much as possible so that as a rule these processes are carried out during 
the 1st semester of the year;
•	 	an AD staff member was recruited to enhance the EMCDDA’s capacity to plan and 
monitor its activities.
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Chapter 3
Declaration of assurance by authorising officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drugs 
Addiction
In my capacity as Authorising Officer
•	 	Declare that the information contained in this report gives a true and fair view (12).
•	 	State that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance 
with the principles of sound financial management, and that the control procedures put in 
place give the necessary guarantees concerning the legality and regularity of the 
underlying transactions.
•	 	This reasonable assurance is based on my own judgment and on the information at my 
disposal, such as the results of the self-assessment, ex post controls, the work of the 
internal audit capability, the observations of the Internal Audit Service and the lessons 
learnt from the reports of the Court of Auditors for years prior to the year of this 
declaration.
•	 	Confirm that I am not aware of anything not reported here which could harm the interests 
of the institution.
Done in Lisbon, on 30 May 2011
Wolfgang götz 
Director
(12)  True and fair in this context means a reliable, complete and correct view on the state of affairs in the 
service.
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Annex 1
Objectives as defined in the EMCDDA’s 2010 Work 
programme
Monitoring and reporting on the drugs problem in Europe
1. Monitoring the drug situation
1.1. Tools and processes
1.1.1. To improve the data management and statistical processes in order to deliver greater 
efficiency and accuracy to the analysis of quantitative and qualitative data sets.
1.1.2. To harmonise and enhance data management and data analysis, including formalising 
processes, improving computing tools and boosting data quality assurance.
1.1.3. To produce a state-of-the-art annual review of developments in drug use and responses in 
Europe located within a broader explanatory conceptual framework (scientific, historical, 
demographical and socio-political).
1.2. Key indicators
1.2.1. To maintain and develop a European expert network.
1.2.2. To increase the quality and comparability of key indicators.
1.2.3. General population surveys (GPS): To promote the reporting of population surveys and 
encourage the collection of data on frequency of use.
1.2.4. Treatment demand indicator (TDI): To improve the performance of and rationalise the TDI 
indicator.
1.2.5. Drug-related deaths indicator (DRD): To acquire a better understanding of drug mortality.
1.2.6. Problem drug use (PDU) and revised problem drug use indicator (PDU-R): To continue to 
develop alternative estimates of problem drug use.
1.2.7. Drug-related infectious diseases indicator (DRID): To consolidate the drug-related infectious 
diseases indicator and improve analysis of trends.
1.3. New developmental areas
1.3.1. To improve data collection and data analysis on polydrug use and vulnerable groups.
1.3.2. To review the monitoring of drug use in custodial settings.
1.3.3. To carry out data collection and analysis activities on crime, drug supply and markets.
1.4. Analysis and innovative strategies
1.4.1 To perform combined cross-indicator analysis to ensure maximum value from data available.
1.4.2 To investigate alternative methods of data analysis.
2. Monitoring responses, interventions and solutions applied to drug-related problems
2.1. Data collection on availability, accessibility and characteristics of responses
2.1.1. To provide a high-quality and comprehensive review of developments in health and social 
responses (HSR) to drugs based on methodologically sound tools configured to best fit 
information availability.
2.1.2. To improve methodological tools and deepen understanding of ratings instruments on 
provision, availability, accessibility and quality of interventions.
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2.1.3. To develop and implement data collection tools in the area of environmental prevention 
strategies.
2.1.4. To improve estimates of public expenditure through fine-tuning of the reporting tools.
2.2. Coherent and systematic set of response indicators in conceptual areas
2.2.1. To develop a coherent and comprehensive strategy for data collection and analysis of 
interventions data.
2.2.2. To introduce an improved set of prevention and early intervention indicators.
2.2.3. To put in place a set of coherent and systematic indicators on treatment availability, 
provision and coverage, and on social reintegration provision.
2.2.4. To report more systematically on harm reduction responses.
2.2.5. To develop a better understanding of the economic analysis of drug markets.
2.2.6. To improve data collection and reporting on responses to drug use and on drug users in 
prison settings.
2.3. Analytical framework for new methodological developments
2.3.1. To further expand cross-indicator analysis between epidemiology and responses.
2.3.2. To improve estimates of non-labelled public expenditure and develop modelling approaches 
for the economic analysis of the drugs phenomenon.
3. Monitoring new trends and developments and assessing the risks of new substances
3.1. Implementation of early warning mechanism
3.1.1. To implement effectively the aspects of the Council Decision on the information exchange, 
risk assessment and control of psychoactive substances (2005/387/JHA) that fall within the 
remit of the EMCDDA, such as the early warning system (EWS) and risk assessment 
exercise.
3.1.2 To explore new sources, improve database and enhance forensic science link.
3.1.3 To ensure effective information exchange through Reitox EWS, with the EMA and Europol.
3.2. Emerging trends
3.2.1. To further develop an integrated approach for monitoring and reporting on emerging 
trends, including case study.
3.2.2. To pilot new data sources and trend-spotting network.
4. Improving Europe’s capacity to monitor and evaluate policies
4.1. Monitor and support tools to assess drug policies
4.1.1. To support Member States in evaluating their national strategies and action plans.
4.1.2. To support reporting on public expenditure, cost of interventions and cost efficiency.
4.1.3. To increase analysis of national laws and legal basis for interventions and enhance their 
visibility.
4.1.4. To provide ongoing support to the EU drug policy review.
4.2. Good practice, guidelines and quality standards
4.2.1. To further develop and encourage exchange of information on evidence-based interventions.
4.2.2. To contribute to the identification and establishment of European quality standards and 
benchmarks for interventions.
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5. Cross-unit projects (CUPs)
5.1. Treatment
5.1.1. To ensure the EMCDDA’s approach to monitoring and reporting on drug treatment is 
coherent and efficient.
5.2. Drug supply and supply reduction
5.2.1 To develop and scale-up EMCDDA activities in monitoring drug supply and supply reduction 
activities and the drug market.
5.3. Prison
5.3.1. To improve and better integrate EMCDDA activities to report on drug use and interventions 
within the prison setting.
5.4. Modelling
5.4.1. To improve capacity for developing statistical and mathematical models of drug use, 
consequences and intervention effects.
III. Supporting drug policy dialogue and technical cooperation
1. International cooperation and collaboration with partners
III.1.1. To strengthen the transfer of know-how and best practices in monitoring the drug situation to 
international and regional partners, and to third countries.
III.1.2 To ensure fruitful collaboration with European and international partners in the drugs field.
2. Technical assistance to candidate and potential candidate countries
III.2.1. To support, coordinate and provide technical assistance to the candidate and potential 
candidate (stabilisation and association process) countries for their participation in 
EMCDDA activities.
IV. Supporting the achievement of results
1. Communicating the EMCDDA’s findings to external audiences
High-quality, timely and accessible products
IV.1.1. To publish high-quality and timely products in line with the targets committed to in the 
2010–12 Work programme.
IV.1.2. To improve the relevance and accessibility of products.
IV.1.3. To maintain and further develop an up-to-date and high-quality online European reference 
point on drugs.
IV.1.4. To improve scientific quality of products and increase scientific output in journals.
IV.1.5. To provide reliable and efficient information, library and documentation services supporting 
the research needs of scientific staff; evaluate, acquire and manage information resources 
for use by the EMCDDA.
Responding better to differentiated needs
IV.1.6. To increase responsiveness to covering issues of relevance to target groups.
IV.1.7. To facilitate access to drug-related science and research and promote cooperation with the 
scientific community.
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Cohesive representation and communication
IV.1.8. To promote a cohesive and shared approach to representation activities across the 
EMCDDA.
‘EMCDDA, your reference point on drugs in Europe’
IV.1.9. To enhance the EMCDDA’s reputation and recognition as the European central reference 
point and authoritative information source in the drugs field.
2. Governance, management and networks
Internal organisation
IV.2.1. To pursue organisational and scientific management solutions that improve scientific 
coordination, organisational effectiveness and efficiency.
Statutory bodies
IV.2.2. To provide support to EMCDDA statutory bodies to facilitate strategic decision-making and 
scientific advice regarding quality of EMCDDA work.
Reitox network
IV.2.3. To assure strategic development of the Reitox network, its visibility and management with a 
view to ensuring high-quality EMCDDA products.
3. Administration and supporting core business
Human resources
IV.3.1. To further develop the implementation and monitoring policies, procedures and tools for 
effective management of the EMCDDA’s human resources (HR).
IV.3.2. Improve human resources management and enhance scientific excellence and recognition of 
EMCDDA staff.
Financial management
IV.3.3. To assure and further enhance appropriate processes and procedures for efficient and 
effective financial management and control.
Accounting
IV.3.4. To ensure that accounting data and related information used for preparing EMCDDA 
accounts and financial statements are accurate and timely through the full use of new 
integrated accounting and reporting system.
Planning and reporting
IV.3.5. To coordinate and administer effectively the planning, reporting and monitoring processes 
of the EMCDDA’s work.
Infrastructure and logistics
IV.3.6. To develop safety at work, sound environmental management and security in the buildings, 
including reducing utility costs and promoting use of renewable energy.
IV.3.7. To provide a suitable work environment and related services, and improve efficiency and 
effectiveness through promoting a customer-oriented approach.
ICT
IV.3.8 To ensure successful and efficient delivery of results through quality, cost-effective and timely 
ICT support services, infrastructure and solutions.
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Organisational chart 2010
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Annex 3
Breakdown of EMCDDA staff as of 31 December 2010
Contract agents (CA), Temporary agents (TA), Seconded national experts (SNE), Officials
Categories
Grades Officials
Gender
TA
Gender
Male Female Male Female
AD
15 1 1
14
13 2 1 1
12 3 3 5 3 2
11 2 1 1 5 3 2
10 5 2 3
9 1 1  5 4 1
8 2 1 1
7 5 2 3
6 12 1 11
5
Subtotal AD 6 5 1 42 18 24
AST
11 1 1
10
9 1 1
8 1 1 3 2 1
7 1 1 1 1
6 2 2 2 2
5 2 2
4 2 1 1 10 5 5
3 4 2 2
2
1
Subtotal AST 7 2 5 23 12 11
 TOTAL 13 7 6 65 30 35
Function group
Gender Total 
EMCDDA 
staff
Gender
Male Female Male Female
Contract 
agents
IV 103 47 56
III 10 6 4 % 46 54
II 12 1 11 SNE 1
I 3 3
Administrator = AD 
Assistant = ASTTotal CA 25 10 15
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Number of staff
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Annex 4
Outputs and products
Annual reporting
2010 Annual report: the state of the drugs problem in Europe, EMCDDA, Lisbon, November 
2010.
A yearly overview of the drug phenomenon in Europe.
Available in 22 languages — all EU official languages (except Maltese and Gaelic), plus 
Norwegian.
Cat.	No:	TD-AC-10-001-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/
SK/SL/SV-C
http://www.emcdda.europa.eu/publications/annual-report/2010	(16	349	downloads	in	2010)
Also	presented	online	in	EN:
http://www.emcdda.europa.eu/situation/analysis
Selected issues 2010
Trends in injecting drug use in Europe, EMCDDA, Lisbon, June 2010.
Cat. No: TD-SI-09-003-EN-C
http://www.emcdda.europa.eu/publications/selected-issues/injecting	(1	537	downloads	in	2010)
Accompanied	by	a	multilingual	summary	available	in	23	languages:
http://www.emcdda.europa.eu/html.cfm/index108589EN.html
Problem amphetamine and methamphetamine use in Europe, EMCDDA, Lisbon, November 
2010.
Cat.	No:	TD-SI-10-001-EN-C
http://www.emcdda.europa.eu/publications/selected-issues/problem-amphetamine	(639	
downloads	in	2010)
Accompanied	by	a	multilingual	summary	available	in	22	languages:
http://www.emcdda.europa.eu/publications/selected-issues/problem-amphetamine/summary
Treatment and care for older drug users, EMCDDA, Lisbon, November 2010.
Cat. No: TD-SI-10-002-EN-C
http://www.emcdda.europa.eu/publications/selected-issues/older-drug-users	(724	downloads	in	
2010)
Statistical bulletin (web-based)
The epidemiological basis on which the Annual report is based, with over 350 tables and 
100 graphics collated by the EMCDDA from the information submitted by the network of 
Reitox national focal points.
Available as a website in EN: http://www.emcdda.europa.eu/stats10
Country overviews
Summaries of the national drug situation, key statistics and a barometer showing the drug 
use prevalence position in each country. Available online in EN and in national language:
http://www.emcdda.europa.eu/publications/country-overviews
Country overviews 2010 (FSU)
Summaries of the national drug situation showing the drug use prevalence position in seven 
former Soviet Union countries: Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Ukraine 
and Uzbekistan
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Available online in EN:
http://www.emcdda.europa.eu/publications/country-overviews
General report of activities
General report of activities 2009, EMCDDA, Lisbon, June 2010.
A detailed progress report of the EMCDDA’s activities over a 12-month period.
http://www.emcdda.europa.eu/publications/general-report-of-activities/2009
Annual	accounts	2009,	EMCDDA,	Lisbon,	August	2010.
http://www.emcdda.europa.eu/html.cfm/index115776EN.html
Outputs linked to the implementation of the Council Decision on new 
psychoactive substances (2005/387/JHA)
Risk assessment of new psychoactive substances — operating guidelines, EMCDDA, Lisbon, 
March 2010.
Cat. No: TD-78-09-810-EN-D
This publication is a revision of the Guidelines for the risk assessment of new synthetic drugs 
(published in the same series, in 1999).
http://www.emcdda.europa.eu/html.cfm/index100978EN.html
Risk assessment report of a new psychoactive substance: 4-methylmethcathinone 
(mephedrone), EMCDDA, Lisbon, September 2010.
This publication presents the summary findings and the conclusions of the risk assessment 
carried out by the EMCDDA’s extended Scientific Committee of mephedrone.
http://www.emcdda.europa.eu/html.cfm/index116639EN.html (1 070 downloads in 2010)
EMCDDA Monographs
Harm reduction: evidence, impacts and challenges, EMCDDA, Lisbon, April 2010.
Cat. No: TD-AL-10-010-EN-C
http://www.emcdda.europa.eu/publications/monographs/harm-reduction (5 078 
downloads in 2010)
EMCDDA Manuals/Guidelines
Guidelines for collecting data on retail drug prices in Europe: issues and challenges, 
EMCDDA, Lisbon, April 2010.
Cat. No: TD-30-09-242-EN-C
http://www.emcdda.europa.eu/publications/manuals/prices (794 downloads in 2010)
Prevention and Evaluation Resources Kit (PERK), EMCDDA, Lisbon, June 2010.
Cat.	No:	TD-32-09-194-EN-C
http://www.emcdda.europa.eu/publications/perk (1 510 downloads in 2010)
Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users, 
EMCDDA, Lisbon, November 2010.
Cat. No: TD-30-09-243-EN-C
http://www.emcdda.europa.eu/publications/manuals/testing-guidelines (1 311 downloads 
in 2010)
EMCDDA–Europol joint publications
Cocaine: a European Union perspective in the global context, EMCDDA and Europol, 
Lisbon, April 2010.
Cat. No: TD-38-09-002-EN-C
Available	in	EN	and	ES.
http://www.emcdda.europa.eu/publications/joint-publications/cocaine (5 267 downloads in 
2010)
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Drug profiles
Objective and scientifically sound descriptions of controlled drugs.
Three published in 2010: khat, synthetic cathinones, synthetic cocaine derivatives. All others 
were updated. Available as a website in DE, EN and FR.
http://www.emcdda.europa.eu/publications/drug-profiles
Thematic papers
Children’s voices. Experiences and perceptions of European children on drug and alcohol 
issues, EMCDDA, Lisbon, May 2010.
http://www.emcdda.europa.eu/publications/thematic-papers/childrens-voices (1 953 
downloads in 2010)
Drugnet Europe
Drugnet Europe
The EMCDDA’s quarterly newsletter. Provides regular information on the Agency’s activities 
to a broad readership. Four editions in 2010 (69, 70, 71, 72). Available in EN.
http://www.emcdda.europa.eu/publications/drugnet
Also available as a website:
http://www.emcdda.europa.eu/publications/drugnet/online
Media products
News releases
14 news releases
No 1 — EU drugs agency publishes major work on harm reduction: past, present and future
Harm reduction moves to the mainstream
(21.4.2010) DE/EN/FR/PT
No 2 — Record number of new drugs reported in 2009, says report
EMCDDA–Europol annual report reviews new drugs entering market
(23.4.2010) DE/EN/FR/PT
No 3 — Latest analysis of cocaine market highlights ‘secondary extraction’ laboratories in 
Europe 
EMCDDA and Europol launch in-depth review of cocaine market
(29.4.2010) DE/EN/ES/FR/PT
No 4 — Council calls on EU scientific experts to assess risks of mephedrone
New drug placed under official scrutiny across Europe
(27.5.2010) DE/EN/FR/PT
No 5 — Injecting drug use — stable or declining in most European countries
26 June: International day against drug abuse and illicit trafficking
(24.6.2010) DE/EN/FR/PT
No 6 — EU drugs agency explores cooperation with Europe’s closest neighbours
Boosting drug monitoring capacity across Europe and beyond
(11.10.2010) DE/EN/FR
No 7 — EU drugs agency presents the latest facts, figures, trends and analysis
Annual report 2010: the state of the drugs problem in Europe
(13.10.2010) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/
NO
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No 8 — EMCDDA and CICAD–OAS launch joint handbook on building national drug 
observatories 
Developing drug information networks
(18.10.2010) EN/ES/FR
No 9 — Conference to lay groundwork for monitoring drug markets, crime and supply 
reduction
First European conference on drug supply indicators
(20.10.2010) DE/EN/FR
No 10 — Cecilia Malmström: ‘Enhanced monitoring of the movement of illegal drugs across 
EU borders will help our efforts to tackle organised crime’
Annual report 2010: the state of the drugs problem in Europe
(10.11.2010) EN
No 11 — Europe faces new challenges posed by changes in drug supply and use
Annual report 2010: highlights
(10.11.2010) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/NO
No 12 — Over 1 million drug users a year in treatment, but considerable challenges remain
Annual report 2010: responding to the drugs problem 
(10.11.2010) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/NO
PowerPoint presentation: Headlines 2010 Annual report
(10.11.2010) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/NO
MP3 files of comments from the EMCDDA Director on the Annual report 2010  
http://www.emcdda.europa.eu/about/press/audio
No 13 — ‘Drug problems have no age limits’ — more older drug users seeking help, says 
EMCDDA 
Older drug users: a growing issue for Europe’s treatment services 
(10.11.2010) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/NO
No 14 — EU drugs agency launches new guidelines for HIV testing in injecting drug users
1 December: World AIDS Day
(30.11.2010) EN
Fact sheets
9 fact sheets available mostly only in EN
Fact sheet 1: EU drugs agency signs accord with Ukrainian Ministry of Health
(28.1.2010) Memorandum of understanding signed today
Fact sheet 2: EMCDDA and Europol Directors review new substances entering Europe’s illicit 
drug market
(25.3.2010) EMCDDA–Europol Cooperation
Fact sheet 3: Children’s voices — experiences and perceptions of children around drugs and 
alcohol
(28.5.2010) 1 June: International Children’s day
Fact sheet 4: EU drugs and medicines agencies sign agreement today in London
(10.6.2010) EMCDDA and EMA step up cooperation
Fact sheet 5: Twenty-five years’ experience in the cross-border collection and analysis of 
information
(6.9.2010) Profile — EMCDDA director Wolfgang Götz
Fact sheet 6: EU drugs agency explores cooperation with Europe’s closest neighbours
Boosting drug monitoring capacity across Europe and beyond
(21.9.2010) DE/EN/FR
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Fact sheet 7: EMCDDA and ONDCP Directors compare policy developments and review 
status of cooperation
(29.9.2010) White House drug officials visit EU drugs agency
Fact sheet 8: EU drugs agency signs accord with Council of Europe’s Pompidou Group
(3.11.2010) Memorandum of understanding signed today
Fact sheet 9: European Commissioner John Dalli visits EMCDDA
(8.11.2010) Health and consumer policy
Online tools and web-based resources
EMCDDA public website
The gateway to drug information in Europe
http://www.emcdda.europa.eu
Prevention profiles
http://www.emcdda.europa.eu/prevention-profiles
Treatment alternatives 
http://www.emcdda.europa.eu/html.cfm/index13223EN.html
Drug-related research
http://www.emcdda.europa.eu/themes/research
Best practice portal
A resource for professionals, policymakers and researchers in the areas of drug-related 
prevention, treatment, harm reduction and social reintegration.
http://www.emcdda.europa.eu/best-practice
Including remodelling and launch of Harm reduction module:
http://www.emcdda.europa.eu/best-practice/harm-reduction/methodology
International partners section 
Rewritten and redesigned web area:
http://www.emcdda.europa.eu/about/partners
First European conference on drug supply indicators
Conference programme and key conclusions are available online:
http://www.emcdda.europa.eu/events/supply-indicators
Joint publications
The European Union and the drug phenomenon: frequently asked questions, EMCDDA and 
the European Commission, Lisbon, October 2010.
Cat. No: TD-31-10-542-EN-C
Available in EN and FR.
http://www.emcdda.europa.eu/joint-publications/eu-faq
(568 downloads in 2010)
Building a national drugs observatory: a joint handbook, EMCDDA and CICAD-OAS, 
Lisbon, October 2010.
Cat.	No:	TD-31-10-496-EN-C
Available in EN/ES/FR/HR/IT/TR
http://www.emcdda.europa.eu/publications/joint/ndo-handbook (1 431 downloads in 
2010)
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EMCDDA technical reports, papers, reviews and articles (classified by subject 
area)
Monitoring the drug situation
Degenhardt, L., Mathers, B., Guarinieri, M., Panda, S., Phillips, B., et al. (2010), ‘Reference 
Group to the United Nations on HIV and injecting drug use’, International Journal of Drug 
Policy, September 2010, Volume 21, Issue 5, pp. 347–58.
Griffiths, P., Lopez, D., Sedefov, R., Gallegos, A., Hughes, B., et al. ‘Khat use and 
monitoring drug use in Europe: The current situation and issues for the future’, Journal of 
Ethnopharmacology, 7 May 2010.
Gyarmathy, V.A., Neaigus, A., Li, N., Ujhelyi, E., Caplinskiene, I., et al (2010), ‘Liquid drugs 
and high dead space syringes may keep HIV and HCV prevalence high — a comparison of 
Hungary and Lithuania’, European Addiction Research 2010, Volume 16, Issue 4, pp. 220–
8. Epub, 26 August 2010.
Gyarmathy, V.A., Rácz, J. (2010), ‘Social networks, risk dyads, and their role in the 
epidemiology and prevention of drug related infectious diseases’, Orvosi Hetilap, 8 August 
2010, Volume 151, Issue 32, pp. 1289–94. Review in Hungarian.
Gyarmathy, V.A., Rácz, J. (2010), ‘A Hepatitis C vírus és az emberi immunhiányt okozó 
vírus járványtana magyarországi injektáló kábítószer-használók körében – hogyan tovább?’ 
(The epidemiology of Hepatitis C and human immunodeficiency virus infections among 
injecting drug users in Hungary – what’s next?]), Orvosi Hetilap, 1 March 2010, Volume 
151, Issue 10, pp. 365–71. In Hungarian.
Klempova, D., Zobel, F. (2010), ‘Insights into shared and specific features of intensive drug 
use in Europe’, Nordic Studies on Alcohol and Drugs, Volume 27, pp. 95–100.
Kolarić, B., Štajduhar, D., Gajnik, D., Rukavina, T., Wiessing, L. (2010), ‘Seroprevalence of 
blood-borne infections and population sizes estimates in a population of injecting drug users 
in Croatia’, Cent European Journal of Public Health 2010, Volume 18, No 2, pp. 104–109.
Mathers, B., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., et al., for the 2009 
Reference Group to the UN on HIV and Injecting Drug Use (2010), ‘HIV prevention, 
treatment, and care services for people who inject drugs: a systematic review of global, 
regional and national coverage’, Lancet, 1 March 2010.
Mounteney, J., Haugland, S. and Skutle, A. (2010), ‘Truancy, alcohol use and alcohol-
related problems in secondary school pupils in Norway’, Health Education Research, 9 
September 2010.
Olszewski, D., Matias, J., Monshouwer, K., Kokkevi, A. (2010), ‘Polydrug use among 15- to 
16-year olds: Similarities and differences in Europe’, Drugs: Education, Prevention, and 
Policy, 2010, Volume 17, No 4, pp. 287–302.
Pirona, A., Morgan, M.J., ‘An investigation of the subacute effects of ecstasy on 
neuropsychological performance, sleep and mood in regular ecstasy users’, Journal of 
Psychopharmacology, February 2010, Volume 24, No 2, pp. 175–85. Epub, 7 April 2009.
Vickerman, P., Hickman, M., May, M., Kretzschmar, M., Wiessing, L., ‘Can HCV prevalence 
be used as a measure of injection-related HIV-risk in populations of injecting drug users? An 
ecological analysis’, Addiction, February, Volume 105, No 2, pp. 311–8. Epub, 16 
November 2009.
Wiessing, L., Blystad, H., ‘EMCDDA publishes guidelines on testing for HIV, viral hepatitis 
and other infections in injecting drug users’, Euro Surveillance 2010, Volume 15, No 48, 
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pii=19735. Available online: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=19735
Wiessing, L., Klempová, D., Hedrich, D., Montanari, L., Gyarmathy, V.A., ‘Injecting drug use 
in Europe: stable or declining’, Euro Surveillance, 1 July 2010, Volume 15, No 26, pii: 
19604. Available online: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=19604
Monitoring responses, interventions and solutions applied to drug-related problems
Montanari, L., Serafini, M., Maffli, E., Busch, M., Kontogeorgiou, K., et al., ‘Gender and 
regional differences in client characteristics among drug treatment clients in Europe’, Drugs: 
Education, Prevention and Policy. Posted online on 7 September 2010.
Quaglio, G., Pattaro, C., Gerra, G., Mezzelani, P., Montanari, L., et al. (2010), 
‘Buprenorphine in maintenance treatment: Experience among Italian physicians in drug 
addiction centres’, The American Journal on Addictions, Volume 19, pp. 222–230.
Simon, R., Pirona, A. (2010), ‘Ältere Drogenkonsumenten in Behandlung: ein zunehmendes 
Problem’, Sucht, Volume 56 (3–4), pp. 254–256.
Zobel, F. (2010), ‘Usage de drogue et réduction des risques en Europe’ in Expertise 
collective sur la réduction des risques infectieux chez les usagers de drogue’ Paris, INSERM, 
2010, pp. 403–416.
Monitoring new trends and developments and assessing the risks of new substances
Griffiths, P., Sedefov, R., Gallegos, A., Lopez, D. (2010), ‘How globalisation and market 
innovation challenge how we think about and respond to drug use: ‘‘Spice’’ — a case 
study’, Addiction 2010, Volulme 105, No 6, pp. 951–953.
Griffiths, P., Lopez, D., Sedefov, R., Gallegos, A., Hughes, B., et al. (2010), ‘Khat use and 
monitoring drug use in Europe: the current situation and issues for the future’, Journal of 
Ethnopharmacology 2010, Volume 132, No 3, pp. 578–583.
Hillebrand, J., Olszewski, D., Sedefov, R. (2010), ‘Legal highs on the Internet’, Substance 
Use and Misuse, Volume 45, pp. 330–340.
Mounteney, J., Fry, C., McKeganey, N., Haugland, S. (2010), ‘Challenges of reliability and 
validity in the identification and monitoring of emerging drug trends’, Substance Use and 
Misuse, 2010, Volume 45(1–2), pp. 266–87.
Mounteney, J., Stoove, M., Haugland, S. (2010), ‘Monitoring emerging drug trends: 
Psychometrics and validity in earlier warning systems’, Addiction Research and Theory, 
pp. 1606–6359 (print)/1476-7392 (online), 2010.
Sedefov, R., Gallegos, A., King, L., Lopez, D., Auwärter, V., et al. (2010), ‘Understanding 
the ‘‘Spice’’ phenomenon’, Toxichem Krimtech 2010, Volume 77, No 1,
pp. 29–45.
Simon, R., Sedefov, R., ‚Nachrichten aus der EBDD. ‘Spice’ – Ein Bericht zur Situation in 
Europa.’ Sucht 2010, Volume 56(3–4), pp. 213–214.
Improving Europe s´ capacity to monitor and evaluate policies
Faggiano, F., Vigna-Taglianti, F., Burkhart, G., Bohrn, K., Cuomo, L., et al. and the EU-Dap 
Study Group (2010), ‘The effectiveness of a school-based substance abuse prevention 
program: 18-month follow-up of the EU-Dap cluster randomised controlled trial’, Drug and 
Alcohol Dependence, 15 January 2010 (Epub ahead of print).
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Ferri, M., Davoli, M., Perucci, C.A. (2010), ‘Heroin maintenance for chronic heroin-
dependent individuals’, Cochrane Database Systematic Reviews, 4 August 2010, No 8, 
CD003410. Review
Montanari, L., Hughes, B., Zobel, F., Ballotta, D. (2010), ‘Le risposte politica dell’Europa a 
livello comunitario e nazionale al problema della droga in Europa’, Sanza, M., Ugolini, P., 
Teoria e prassi delle notti sicure, Angeli, F., Milan, 2010.
Prieto, L. (2010), ‘Labelled drug-related public expenditure in relation to gross domestic 
product (GDP) in Europe: a luxury good?’, Substance Abuse Treatment Prevention Policy, 17 
May 2010, Volume 5, No 9.
Salamina, G., Diecidue, R., Vigna-Taglianti, F., Jarre, P., Schifano, P., et al., ‘VEdeTTE Study 
Group. Effectiveness of therapies for heroin addiction in retaining patients in treatment: 
results from the VEdeTTE study’, Substance Use and Misuse, October 2010, Volume 45, No 
12, pp. 2076–92. Contributor: Ferri, M.
Cross-unit projects (CUPs)
Laniel, L., Carpentier, C., Kasecker, R., Simon, R. (2010), ‘Europäische Drogenmärkte in 
einer globalisierten Welt‘, Suchtmagazin, No 6, 2010.
Laniel, L., Zobel, F., Lopez, D., «L’offre et la demande de drogues illicites en Europe» 
INHESJ/ ONDRP, Rapport 2010, Paris.
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Annex 5
Key events, visits, participation in conferences and technical 
meetings, 2010
Date Venue Title of the event (+ title of the presentation, if applicable)
Monitoring the drug situation
14–15 January Sliema Conference: qualitative research and policy
20–22 January San Diego National Institute on Drug Abuse (NIDA) Community Epidemiology Work Group 
(CEWG) meeting
25 February Brussels Youth drinking and binge drinking: mapping, understanding, and preventing a problem
8–9 March Lisbon Working group on TDI revision
23–26 March Cairo Med-Net — Pompidou Group
(Presentation: The Treatment Demand Indicator: general information and main results 
from the last data)
30 March Luxembourg 4th Health Information Committee meeting
15 April Lisbon Visit of Australian experts
(Presentation: TDI indicator: general information and main results)
2–6 May Helsinki Q2010, European conference on quality in official statistics
7 May Porto Lecture in course ‘Epidemiology of Infectious Diseases’, Institute of Public Health, 
University of Porto
(Presentation: Epidemiology of infectious diseases in injecting drug users in Europe)
10 May London UK focal point on drugs workshop — EMCDDA key indicator: drug-related deaths and 
mortality of drug users
(Presentation: EMCDDA DRD indicator and reporting requirements for NFPs.
Voluntary Selected issue 2010–11. Mortality related to drug use: a comprehensive 
approach and public health implications.)
12 May Lisbon Expert meeting on monitoring of intensive, problematic and dependent cannabis use
25 May Lisbon Fonte steering group meeting with NFP representatives
28 May Madrid Drug coordinators meeting: polydrug use thematic meeting
31 May–4 June Lausanne 36th annual alcohol epidemiology symposium of the Kettil Bruun Society
(Presentation: The use of stimulants other than cocaine among patients entering drug 
treatment in Europe: main findings and trends)
31 May–4 June Denver Annual meeting of the Society for Prevention Research
(Presentation: EU–US cooperation in prevention research)
9–11 June Boston Community Epidemiology Work Group (CEWG)
12–16 June Akureyri Annual plenary ESPAD meeting
17–18 June Luxembourg Kick-off meeting of the EC–funded project ‘Heath Promotion for Young Prisoners’ (HPYP)
(Presentation: Monitoring drug use and related interventions among prison population in 
Europe: the EMCDDA activities and perspectives for the future)
22–23 June Lisbon Annual expert meeting on prevalence and patterns of drug use among the general 
population key indicator (General Population Survey)
23–27 June Warsaw Pompidou Group seminar
24 June Lisbon Workshop on data analysis on polydrug use on harmonised GPS databases (CY, DK, 
FR, UK) ‘Data laboratory’
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Date Venue Title of the event (+ title of the presentation, if applicable)
1–2 July Lisbon Workshop on mortality cohort studies ‘Data laboratory’
21–26 August Oslo Meeting of the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) 
6–17 September London Advanced course on epidemiological analysis
16–17 September Stockholm ECDC Technical consultation ‘Evidence synthesis and guidance development to increase 
the effectiveness of HIV testing’
20 September London Meeting on ‘Research drug treatment: future research needs’
20–21 September Lisbon Annual expert meeting on the Treatment Demand Indicator (TDI)
28–30 September Berlin ECDC expert meeting ‘STI and HIV surveillance in EU/EEA’
30 September–2 
October
Prague Conference ‘Urban drug policies in the globalised world’
11–13 October Vienna UNODC Expert group on data collection
11–13 October Lisbon Annual expert meeting on Drug Related Infectious Diseases (DRID) key indicator
(Presentations:
1) 2010 DRID expert meeting
2) Revision of Drug–Related Infectious Diseases Indicator
3) Revision of ST9 part 3: slides for the general discussion
4) Future DRID toolkit — comments on draft DRID protocol from 2009 expert meeting)
14–15 October Brussels Hepatitis B and C summit conference
(Presentation: Injecting drug users in Europe: a key at-risk population for hepatitis B and 
C infection)
21–22 October Lisbon Expert meeting: ESPAD Polydrug Group
25–26 October Paris PDU project — technical assistance
28 October Brussels Meeting of the expert group on alcohol, drugs and medicines
8 November Vienna Austrian National Reitox academy on General Population Surveys (participated 
EMCDDA project officer)
11–12 November Lisbon Annual expert meeting on Drug-related death key indicator
12 November Lisbon Meeting with staff of Eurosurveillance
(Presentation: General discussion on possibility for publication)
16 November Zurich Expert group on Swiss Addiction Monitor
22–23 November Luxembourg Workshop on health information and indicators
23 November Lisbon Fonte steering group meeting with NFP representatives
25–26 November Rome 4th Eurolifestyle network meeting
10–11 December Kuala Lumpur The Lancet series symposium ‘HIV in people who use drugs’
13–14 December Lisbon EU expert meeting on the key epidemiological indicator Problem Drug Use
Monitoring responses, interventions and solutions applied to drug-related problems
22 February Budapest Consumption rooms: perspectives in Europe and in Hungary
7 June Berlin FreD goes Net
(Presentation: Drug laws in the EU)
14 June Vienna Rights based approach to HIV/AIDS
26 July–6 August Essex Essex summer school in social science
3 November Bilbao International scientific meeting of drug consumption rooms
(Presentation: Heroin prescription programmes in Europe: a general overview)
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Date Venue Title of the event (+ title of the presentation, if applicable)
5 November Istanbul European Network on Exchange Early Detection Drug-consumption (ENEEDD) project 
meeting
8–9 November Amsterdam First annual EUSPR conference
Monitoring new trends and developments and assessing the risks of new substances
13 January London Meeting with the EMA for the Working arrangement between the EMA and the EMCDDA
(Presentation: Action on new drugs — the European Monitoring Centre for Drugs and 
Drug Addiction)
13 January London Visit to Guy’s and St Thomas’ NHS Foundation Trust and King’s Healthcare Partners
14 January London Visit to National Addiction Centre, Institute of Psychiatry, Kings College, meeting with the 
Chairman of the EMCDDA Scientific Committee, researchers and an EU–funded project
23 April Bologna Fashion, marginalisation, goods, diseases: addiction paradigms (‘Moda, marginalità, 
merce, malattia: i paradigmi delle dipendenze’)
(Presentation: Il monitoraggio del fenomeno sostanze legali sul Web (Monitoring of the 
legal drug phenomenon on the web)
8 July London Official meeting of the UK Advisory Council on the Misuse of Drugs (ACMD)
(Presentation: New psychoactive substances: the EU early-warning system and risk 
assessment)
27 August Lisbon Visit of Japanese National Institute of Health Sciences
(Presentation: Overview of the EWS)
31 August Lisbon Visit of the Irish Ministry of Health
(Presentation: The EWS)
30 September–2 
October
Dubrovnik European Society for Social Drug Research: 21st annual conference
(Presentation: Monitoring the ‘legal high’ phenomenon on the web)
13–14 October Brussels Club Health Project: Media influence in night life
(Presentation: Online sales of legal highs including mephedrone)
Improving Europe’s capacity to monitor and evaluate policies
25–26 January Luxembourg Workshop on best practice models for addiction prevention projects funded under the 
Health Programme, organised by the EMCDDA and the EAHC (Executive Agency for 
Health and Consumers)
4–5 March Porto Correlation network (EU-funded project on harm reduction where the new concepts of the 
Best practice portal were presented and discussed)
(Presentations: Drug situation and harm reduction responses in Europe: State of affairs
Models of Good Practice — building common ground for information provision)
15–16 March California 4th annual conference of the International Society for the Study of Drug Policy
(Presentation: Unemployment and Drug Treatment; Panel discussant: Economic recession 
and drug use)
22–24 March Madrid Conferencia Europea sobre Enfoque Integral de Políticas de Drogas
21 June Lisbon Legal Correspondents meeting
24–25 September Bergamo Presentation of evidence-based prevention programmes particularly in the school at the 
IX Italian Congress of Health Psychology
(Presentation: Evidence-based prevention or evidence of prevention?)
17 November Lisbon Expert meeting on a definition of best practice in drug demand reduction
2 December Lisbon Workshop on the grading of recommendations assessment, development and evaluation 
(GRADE instrument) to grade the evidence
International cooperation and collaboration with partners
12–13 January Brussels 4th meeting of the group of experts on the policy needs for data on crime and criminal 
justice, EC/DG Justice
18 January Brussels Horizontal Drugs Group
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Date Venue Title of the event (+ title of the presentation, if applicable)
22 January Lisbon Visit of EMCDDA delegation to MAOC-N
22 January Brussels Meeting of the Expert Group on alcohol drugs medicines and driving
12 February Brussels Horizontal Drugs Group
22–23 February Brussels DG Justice–EMCDDA Coordination Meeting; Public hearing on drug policy in the 
European Union
1–2 March Brussels HDG; EU–LAC; meeting with vice-president of LIBE Committee 
2–5 March Brussels World Customs Organisation (WCO), 29th session of the Enforcement Committee
11 March Brussels The EU Council Committee on Internal Security (COSI) meeting
8–12 March Vienna 53rd Session of the CND, UNODC
24 March Brussels The European governance of addictions: state of play and perspectives
30–31 March Prague Pompidou Group’s Prevention Platform extended meeting evaluation of drug prevention: 
from dogma to useful tool
8 April Brussels Bilateral meeting on drug supply and supply reduction indicators with EC/DG Justice
14–15 April Madrid 4th ECDC Advisory Group for the monitoring of the Dublin Declaration on partnership to 
fight HIV/AIDS in Europe and Central Asia
14–15 April Strasbourg 65th Pompidou Group Permanent Correspondents meeting
26–28 April Madrid Mechanism and drug coordinators high-level meeting
10 May Strasbourg Conference on stimulant abuse treatment, Treatment Platform of the Pompidou Group
(Presentation: Epidemiology of stimulant use and different users’ groups in Europe)
19–20 May Brussels HDG and Troika with Western Balkans and Western Africa
1–5 June Washington Coordination meeting with CICAD, revision final version NDO handbook
8 June Brussels Horizontal Drugs Group
9–11 June Strasbourg Council of Europe Pompidou Group: Airport Group
15 June Paris 66th Pompidou Group Permanent Correspondents meeting
16 June Brussels Coordination meeting between EMCDDA and the European Commission on international 
cooperation issues
22–23 June Lisbon 14th meeting of expert committee on ethical issues and professional standards
24 June Chlewiska koło 
Szydłowca 
(Poland)
Training for policymakers organised by the Pompidou Group
(Presentation: Lecture on Drug policy and research)
26 June Tunis Seminar on the prevention of drugs
(Presentation: L’observation du phénomène de la drogue en Europe, situation et 
perspectives de coopération avec les pays du Maghreb)
4–8 July Brasilia Conference of the Commissão de Seguridade Social e Família (CSSF) of the Federal 
Brazilian Parliament
(Presentation: Políticas na União Europeia: redução de riscos, legislação e prevenção)
9 July Vienna OSCE Conference on combating the threat of illicit drugs and strengthening control of 
precursor chemicals
(Presentation: Cocaine trafficking, markets and use in Europe)
13–15 July Brussels Interservice Group on Drugs; HDG
8 September Tallinn CEPOL, 19th Annual Programme Committee Meeting (APC), dedicated session
13–15 September Brussels HDG; Dublin Group and meeting EU–Russia experts
21–24 September Loures CEPOL, training seminar on southwest Europe organised crime organisations
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Date Venue Title of the event (+ title of the presentation, if applicable)
23–24 September Brussels Coordination meeting DG Justice/DG SANCO/ECDC
24 September Coimbra EU–LAC City Forum — Coimbra, Portugal
(Presentation: Best practice in demand management models of treatment services at the 
local level)
4–7 October Milan The International Society of Addiction Medicine’s (ISAM) 12th Annual Conference
(Presentation: State of the drugs problem in Europe: dynamics, innovations and 
challenges  
The EMCDDA Best practice portal)
5 October Brussels Meeting of the Standing Committee on operational cooperation on internal security 
(COSI)
7 October Brussels CEPOL, European police and judicial systems — study tour 46AP/2010
11–12 October Brussels 10th meeting of the high level specialised dialogue on drugs between the EU and the 
Andean Community and HDG meeting
13–14 October Milan IV Congresso Nazionale FeDerSerD Riva del Garda
17–20 October Montevideo CICAD International meeting of national drug observatories
3 November Strasbourg 67th Pompidou Group Permanent Correspondents meeting
3–4 November Strasbourg 15th Pompidou Group Ministerial Conference
9 November Brussels Horizontal Drugs Group
10 November Bucharest Launch of EMCDDA Annual report
15–17 November Brussels Horizontal Drugs Group and National Drug Coordinators Meeting
18 November Lisbon Experience exchange visit from the ECDC on international cooperation issues
26 November The Hague Meeting of the JHA Heads of Agencies
1–3 December Hanoi 4th national scientific conference on HIV/AIDS
14–15 December Valencia WHO ATLAS
16 December Valencia WHO SAIMS
Technical assistance to candidate and potential candidate countries
28–30 April Zagreb IPA III project kick-off meeting
9 September Belgrade National seminar ‘Strengthening cooperation with the EMCDDA in the Republic of 
Serbia’
Supporting the achievement of results
26–28 May Lisbon 42nd Reitox Heads of focal points meeting
28 May Brühl Seminar on drug criminality, German Police University
28–29 June Santander Spanish Presidency seminar ‘Translating research results into the field of drugs and 
addictions’
1–2 July Lisbon Management Board meeting
16 July Lisbon 32nd Scientific Committee meeting
7 September Skopje Reitox academy on EU finances for all IPA beneficiaries
14 September Östersund Information meeting on the EMCDDA, Swedish focal point at the Institute for Public Health
28–29 September The Hague ERA–Net on illicit drugs
30 September–2 
October
Prague 10th Annual meeting of the International Society for Addiction Journal Editors (ISAJE)
10 November Vilnius Presentation of the EMCDDA Annual report
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Date Venue Title of the event (+ title of the presentation, if applicable)
10 November London Marie Curie Initial Training Network (ITN) discussion meeting
15–16 November Lisbon 33rd Scientific Committee meeting
23 November Lisbon Introductory meeting for the Swedish national focal point
24–26 November Lisbon 43rd Reitox Heads of focal points meeting
9 December Lisbon Management Board meeting
13–15 December Lisbon Reitox academy ‘Building national drug observatories and the network of regional drug 
observatories — Progetto NIOD ‘Italian Network of Addiction Observatories’
Transversal work (14)
12–15 January Vienna Open-ended intergovernmental expert group meeting on current drug-related data 
collection tools
28 January Riga Meeting organised by the Latvian NFP — Risk assessment: the National EWS network
(Two presentations on:
1) EMCDDA: Action on new drugs
2) Risk assessment of new psychoactive substances: Operating guidelines)
28 January Kiev Signature of the MoU with Ukraine
29 January Paris Council of Europe Pompidou Group: Preparation meeting for an ad-hoc conference on 
precursors
4–5 February Strasbourg Pompidou Group Criminal Justice Forum
12 February Bilbao Etorkintza conference
(Presentation: La prevención selectiva e indicada)
22 February Brussels DG TREN Expert Working Group on Alcohol, Drugs, Medicines and Driving
25–26 February Lisbon Reitox academy ‘Towards the Selected Issue 2011 ‘History, methods and implementation 
of national treatment guidelines’’
18–19 March Venice Strategic European Inventory on Drugs’ Project (SEID) meeting
23–24 March Lisbon Expert meeting on best practice in responding to drug-related health needs of prisoners 
(meeting co-organised together with EU-funded Connections project)
29–31 March Prague Pompidou Prevention Platform (overview of prevention projects in Europe and evidence 
of effectiveness available)
12–14 April Verona ‘Information and communication technology: utility of information technologies in 
improving practice and decision-making in the addictions field’
(Presentation: European Early warning system (EWS) on new drugs)
15–16 April Schiphol Technical consultation on HIV and TB modelling and methodologies of national HIV 
estimates in the WHO European Region, WHO/Europe and RIVM Netherlands
(Presentations:
1) The EMCDDA modelling study group
2) Modelling Hepatitis C and HIV amongst Injecting drug users (IDUs) — using 
ecological data)
20–21 April Oviedo Socidrogalcol Conference
(Presentation: Valoración de la prevención, con especial referencia a Europa)
20–23 April Lugo EU–LAC drugs summit Europa
25–28 April Liverpool ‘Harm Reduction 2010: International Harm Reduction Association (IHRA) 21st 
International Conference’
(Presentation: State of Second Generation HIV Surveillance for IDUs in Europe)
3–4 May Lisbon Study on the development of an EU Framework for minimum quality standards and 
benchmarks in drug demand reduction (EQUS)
(14)  The events presented in this section cover the work of several of the EMCDDA’s units and/or sectors and subject areas, as set-out in the Work 
programme objectives listed in Annex 1.
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Date Venue Title of the event (+ title of the presentation, if applicable)
5 May Brussels 14th HIV/AIDS think tank meeting, European Commission
Health and Consumer Protection Directorate-General
17 May Lisbon Coordination meeting with Northern Dimension Public Health and Social well being 
(NDPHS)
(Presentation of epidemiological information on prison and drug)
18 May Brussels Horizontal Drugs Group meeting
(Presentation: EMCDDA- Europol 2009 Annual Report on the implementation of Council 
Decision 2005/387/JHA)
18–20 May Bled 16th ENFSI (European Network of Forensic Science Institutes) Drugs Working Group 
meeting
(Presentation: European Early warning system on new drugs — How technological 
innovation challenges how we think about and respond to drugs) 
20 May Brussels Troika with Western Balkans
(Presentation: Presentation of the current cooperation between Western Balkan countries 
and the EMCDDA)
20–21 May Vienna HIPP Steering Group Meeting for Prison and Health
20–21 May Stockholm Preparatory meeting European Society for Prevention Research (EUSPR)
25 May Frankfurt SDDCare — Senior Drug Dependents and Care Structures European conference (meeting 
of project advisory group)
3–4 June Lisbon 10th Annual meeting of the Reitox early warning system network 
(Presentations:
1) The Reitox EWS: implementation and results in 2009
2) Anthrax outbreak among heroin users in the United Kingdom and Germany 2009–10
3) Europol–EMCDDA Joint Report on 4-methylmethcathinone
4) Discussion on the criteria assessed for launching the collection of information of a 
Joint Report
EMCDDA, Risk assessment of new psychoactive substances — Operating guidelines
5) Online sales of: MDAI ‘Spice’
6) Prevalence of ‘legal highs’
7) Bergen Earlier Warning System (BEWS)
8) Introduction to the parallel workshops: Main elements of the national EWSs
9) Methodology for monitoring the Internet
10) EMCDDA snapshots
11) Methodology for monitoring the Internet — Brainstorming
12) Monitoring misuse of medicinal products in Europe
13) Legal Responses to New Psychoactive Substances in EU Typologies, characteristics 
and speed
14) Hospital emergencies data. Possible usefulness, limitations and some examples
15) Discussion: European Database on New Drugs/European Inventory of Forensic 
Science Laboratories)
7–9 June Zürich ClubHealth 2010 Conference
(Presentation: Poly-drug use: similarities and differences in Europe)
9 June Lisbon Visit of Joint Interagency Task Force South (JIATFS)
(Presentation: EMCCDA Cooperation with Europol)
9–11 June Milan EU standard in prevention concluding meeting (meeting with the project leaders of the 
two EU funded projects on minimal standards in prevention and in prevention treatment 
and harm reduction, to avoid duplication of efforts)
10 June London Directors meeting for the official signing of the EMA–EMCDDA working agreement
(Presentation: EU action on new drugs: EMCDDA–EMA cooperation)
10–11 June Brussels European Commission project: European standards in evidence for drug prevention
11–15 June Scotsdale 2010 National Institute on Drug Abuse (NIDA) international forum: drug abuse research, 
policy, and the public good, third meeting of the International Women’s and Children’s 
Health and Gender Group.
(Presentation: Drug treatment programs focusing on women in Europe; Selective 
prevention: addressing vulnerability to problem drug use in Europe (poster))
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Date Venue Title of the event (+ title of the presentation, if applicable)
16 June Brussels First meeting of the Commission’s ad-hoc working group on the assessment and possible 
amendment of Council Decision 2005/387/JHA
(Presentation: The EU Early-warning system: implementation and results in 2005–10)
17–18 June Lisbon EMCDDA Reitox academy ‘The evaluation of national drug strategies and action plans’
24–25 June London Second Connections international prison conference
(Presentation: Organising and chairing workshops on Monitoring health responses to 
drug use in prison, and on Post-release mortality)
25 June Brussels European Actions on Drugs
28–29 June Vienna Expert consultation on ARQ  
29–30 June London Expert meeting on wholesale drug prices in Europe
(Presentation: Putting into context)
4 July Torino European Science Open Forum (ESOF) conference
14 July Brussels ‘Respect of human rights, health and dignity in prisons. How can civil society 
contribute?’, TAIEX
18–23 July Vienna XVIII International AIDS Conference, including multiple side meetings
(Presentation: Injecting Drug Use in Europe: Challenges for Drug and HIV Policies)
13 September Luxembourg Project SRAP — Addiction prevention within Roma and Sinti Communities, meeting of the 
Advisory Group
15 September Brussels Political dialogue with Ukraine
(Presentation of the current cooperation between Ukraine and the EMCDDA)
15 September Brussels Political dialogue with Russia
(Presentation of the current cooperation between the Russian Federation and the 
EMCDDA)
22 September Lisbon European exchange on the practice and current issues in opioid substitution treatment in 
General Practitioners’ settings
22–26 September Tübingen Symposium on urban lifestyles
(Presentation: Ältere Drogenkonsumenten in Behandlung: Ein zunehmendes Problem
The view of the EMCDDA — Time series and evidence of international differences of 
drug use)
29 September Lisbon Visit of Office of National Drug Control Policy (ONDCP) high representatives
29–30 September Belgrade First seminar on synthetic drugs and chemical precursors in the West Balkans zone
(Presentations:
1) Early warning system — a key element of national drug observatories in Europe
2) Mephedrone — risk assessment)
30 September–1 
October
Strasbourg Pompidou Group conference on the prevention of drug precursors’ diversion — 
perspectives
30 September–2 
October
Ohrid, 
Macedonia
South Eastern European and Adriatic Addiction Treatment Network
(Presentation: Availability and trends in drug treatment in the European Union)
1 October Copenhagen Regional Consultation on the Global Health Sector Strategy for HIV/AIDS 2011–15
5–6 October Münster Final Conference of FRED goes net
(Presentation: Early intervention in Europe — status quo and recommendations)
12 October Brussels Best practice portal presented to the Horizontal Drug Group
(Presentation: Good practices for prevention, treatment, harm reduction and 
rehabilitation: the EMCDDA Best practice portal)
12 October Lisbon WHO-Europe and EC/DG SANCO project on scaling-up (Meeting of Project Advisory 
Group)
14–15 October Brussels Seminar on the EU Drug monitoring system, the EMCDDA and the perspectives for 
cooperation with ENP countries
Annex	5
89
Date Venue Title of the event (+ title of the presentation, if applicable)
14–16 October Copenhagen WHO national counterpart meeting on prison health
19–22 October Brussels European conference on drug supply indicators
(Presentations:
1) Introduction, Wolfgang Götz (EMCDDA Director)
2) Where we are and where do we go — the current ‘state of the art’ on monitoring 
drug supply in Europe
3) Organisational and housekeeping issues and Introduction to technical sessions
4) Drug markets — Making the most of different approaches and achieving synergies: 
Chair of the session — Opening remarks, challenges for the afternoon’s work
5) The state of the art — Monitoring drug purity and tablet contents: what are the issues
6) The market — Understanding the scale and dynamics of the European drug market: 
Moderator report
7) Modelling market dynamics: cocaine as a case study
8) The drugs-crime nexus — Making the connections and identifying priorities: Chair of 
the session — Opening remarks, reflections on progress made in day 1, and challenges 
for day 2
9) The state of the art — drug law offences data in Europe: data availability, current 
challenges and the way forward
10) Drug supply reduction in Europe — Setting the agenda for monitoring in Europe: 
Chair of the session — Opening remarks, challenges for the afternoon’s work
11) Some initial thoughts for monitoring drug supply reduction
12) The policing of illicit drugs: Moderator report
13) Next steps towards a European monitoring strategy: Chair of the session — 
Opening remarks, reflections on progress made in day 2, and challenges for day 3
14) Setting the agenda — Making it happen: what we need to do, and who needs to 
do what?: Moderator of the panel discussion
15) Where do we go from here? Conclusions and next steps emerging from the 
conference
16) Closing remarks from Wolfgang Götz)
20 October Rome Project ‘Imp.Ac.T. — Improving Access to HIV/TB testing for marginalized groups’, kick-
off meeting
26–27 October Luxembourg 15th HIV/AIDS think tank meeting (DG SANCO)
2–7 November Cancún 53rd International ICAA (International Council on Alcohol and Addiction) Conference on 
dependencies ‘New challenges new answers’
(Presentation: The accessibility of licit and illicit drugs on the Internet — Early Warning 
Systems)
4 November Oslo Annual report launch
(Presentation: EMCDDA Annual report 2010)
4–5 November Dublin National drugs conference of Ireland 2010: a continuum of care within drugs services
(Presentation: A continuum of care within drugs services: European perspectives)
4–5 November Lisbon Seminar on health promotion for young prisoners (HPYP) and launch of a training 
manual for prison staff (Training Criminal Justice Professionals — TCJP) 
10 November Bratislava Launch of the Annual report in Slovakia
10 November Rome Launch of the Annual report in Italy
10 November Larnaca Launch of the Annual report in Cyprus
10 November London European Masters in Drugs and Alcohol Studies (EMDAS) pilot session
11–13 November Lisbon European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) 
Conference 2010
(Presentation: HIV AIDS mortality surveillance and mortality statistics in the ART era: 
large discrepancies call from improving data systems in Europe)
12 November Thessaloniki Presentation of Annual report 2010 together with Best practice in the areas of treatment 
and harm reduction
26 November The Hague Annual coordination meeting with Europol to review the list of new substances and 
decide on Joint Reports 
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Date Venue Title of the event (+ title of the presentation, if applicable)
26 November Berlin ‘Drogen und Haft’
30 November–2 
December
Rabat MedNet regional seminar to lay the foundations for national drug observatories/
resource centres
(Presentation of the handbook on building NDOs and on the perspectives for 
cooperation between the EMCDDA and Mediterranean countries)
6 December Brussels Steering Committee meeting of the study on the development of an EU Framework for 
minimum quality standards and benchmarks in drug demand reduction (EQUS)
14–15 December Brussels Fifth meeting of the expert group on the policy need of data on crime and criminal 
justice
20–21 December Brussels Meeting with DG Justice, Meeting of Horizontal Working Party on Drugs
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Annex 6 
Members of the EMCDDA’s statutory bodies
Members of the Management Board
The Management Board consists of one representative from each Member State, two 
representatives of the European Commission, two independent experts particularly 
knowledgeable in the field of drugs designated by the European Parliament and one 
representative from each country which has concluded an agreement with the EMCDDA. 
Non-voting observers, such as from international organisations with which the agency 
cooperates, may be invited to the Management Board meetings.
Country Member Substitute
Belgium Claude GILLARD (Vice-
Chairman)
Philippe DEMOULIN
Bulgaria Tzveta RAICHEVA
Czech Republic Jindril VOBOŘIL Lucia KISSOVA
Denmark Mogens JØRGENSEN Mie SAABYE
Germany Mechthild DYCKMANS Dirk LESSER
Estonia Maris SALEKEŠIN Andri AHVEN
Ireland Geraldine LUDDY Alan BELL
Greece Minerva-Melpomeni MALLIORI Konstantinos GAZGALIDIS
Spain Nuria ESPÍ DE NAVAS Maria Sofia ARAGON 
SANCHEZ
France Etienne APAIRE Julien EMMANUELLI
Italy Giovanni SERPELLONI Elisabetta SIMEONI
Cyprus Stelios SERGIDES
Latvia Maris TAUBE
Lithuania Audroné ASTRAUSKIENÉ Povilas RADZEVIČIUS
Luxembourg Frank GANSEN Mike SCHWEBAG
Hungary Peter PORTÖRÖ
Malta Richard MUSCAT
Netherlands Marcel DE KORT
Austria Franz PIETSCH Johanna SCHOPPER
Poland Piotr JABŁOŃSKI Bogusława BUKOWSKA
Portugal João GOULÃO (Chairman) Manuel CARDOSO
Romania Ioan-Nicolae CABULEA Bogdan IASNIC
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia Alojz NOCIAR Dana LÓZIOVÁ
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Country Member Substitute
Finland Tapani SARVANTI Kari HAAVISTO
Sweden Ralf LÖFSTEDT 
United Kingdom John McCRACKEN Anna RICHARDSON
European Commission Aurel CIOBANU-DORDEA  
Dana SPINANT 
Michael HÜBEL  
Caroline HAGER
European Parliament Barbara DÜHRKOP DÜHRKOP  
Carla ROSSI
Hubert PIRKER 
Carmela COSTA
Norwegian representatives Lilly Sofie OTTESEN Jon-Olav ASPÅS
Observers
Scientific Committee Michael FARRELL
Reitox Spokesperson Alan LODWICK
UNODC Gilberto GERRA
Council of Europe Pompidou Group Thomas KATTAU
WHO Haik NIKOGOSIAN
Members of the Executive Committee
The Management Board is assisted by an Executive Committee. The Executive Committee is 
made up by of the Chairperson and the Vice-Chairperson of the Management Board, two 
other members of the Management Board representing the Member States and appointed 
by the Management Board and two representatives of the European Commission. The 
Executive Committee prepares the decisions of the Management Board, and assists and 
advises the Director.
João GOULÃO PT (Chairman of the Management Board)
Claude GILLARD BE (Vice-Chairman of the Management Board and Chair of the 
Budget Committee)
Franz PIETSCH AT
Piotr JABŁOŃSKI PL
Aurel CIOBANU-DORDEA European Commission
Dana SPINANT European Commission
Wolfgang GÖTZ (Director)
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Members of the Scientific Committee
The members of the Scientific Committee are selected for their independence and proven 
expertise in a particular field/speciality, as indicated below.
Issue Name Country
Legal and criminal justice Krysztof KRAJEWSKI Poland
Brice DE RUYVER Belgium
Risk assessment and basic research Fernando RODRIGUEZ FONSECA Spain
Jean-Pol TASSIN France
Political and institutional framework Henri BERGERON France
Irmgard EISENBACH-STANGL Austria
Henk GARRETSEN Netherlands
Epidemiology Marina DAVOLI Italy
Björn HIBELL Sweden
Dirk KORF Netherlands
Matthew HICKMAN UK
Methodological issues Gerhard BÜHRINGER Germany
John STRANG UK
Best practice and interventions Michael FARRELL Ireland
Richard VELLEMAN UK
Economic issues Anne-Line BRETTEVILLE JENSEN Norway
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Annex 7 
Use of the available resources in 2010
Activity-based management presentation of the EMCDDA 2010 budget in accordance with  
the content and costs of the 2010 Work programme
ABM presentation of the EMCDDA 2010 budget in accordance with the content and costs of the 2010 Work programme
Revenues
Initial budget 2nd BRS 3rd BRS Final budget Initial budget
E. C. Subsidy (Under Budget Lines 
18 07 01 01 et 18 07 01 02) 15 000 000 15 000 000 IPA 3 500 000
Norway contribution 398 748 1 575 400 323
Turkey contribution 100 000 -100 000 0
SANCO Project 100 000 -100 000 0
TOTAL 15 498 748 1 575 -100 000 15 400 323
Expenditure (direct costs by programme commitments)
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget
EPI 2 037 574 2 072 574 2 071 511 300 615 317 197 307 869 2 338 189 2 389 771 2 379 380
RES 1 227 210 1 154 210 1 153 387 154 941 189 926 179 626 1 382 151 1 344 136 1 333 013
SCD 420 626 353 626 352 858 102 000 94 905 79 387 522 626 448 531 432 245
Reitox subvention 2 594 497 2 487 086 2 487 086
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 2 — Functioning allocated Title 2  
Functioning  
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Communication 885 111 885 111 846 846 90 000 81 398 79 840 1 043 356 1 143 563 1 114 032 2 018 467 2 110 072 2 040 718
Reitox 754 622 674 622 659 182 0 0 0 190 000 158 630 151 626 944 622 833 252 810 808
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 2 — Functioning allocated Title 2  
Functioning  
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Direction 807 980 797 980 795 217 0 0 0 210 000 178 752 168 771 1 017 980 976 732 963 988
Administration 1 857 845 2 017 345 2 016 081 1 446 480 1 464 788 1 399 848 56 400 42 400 39 330 3 425 725 3 589 533 3 543 325
Administration (training and recruitment) 65 000 65 000 88 066
ICT 653 032 688 532 688 143 581 459 520 753 507 439 20 000 11 925 6 088 1 254 491 1 221 210 1 201 670
Programme Title 1 — Salaries
Title 1  
Salaries 
executed
Title 2 — Functioning
Title 2  
Functioning  
executed
Title 3 — Activities
Title 3  
Activities  
executed
Total programme direct costs
Total programme 
direct costs 
executed
IPA 3 85 000 46 031 2 500 0 412 500 379 112 500 000 425 143
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Activity-based management presentation of the EMCDDA 2010 budget in accordance with  
the content and costs of the 2010 Work programme
ABM presentation of the EMCDDA 2010 budget in accordance with the content and costs of the 2010 Work programme
Revenues
Initial budget 2nd BRS 3rd BRS Final budget Initial budget
E. C. Subsidy (Under Budget Lines 
18 07 01 01 et 18 07 01 02) 15 000 000 15 000 000 IPA 3 500 000
Norway contribution 398 748 1 575 400 323
Turkey contribution 100 000 -100 000 0
SANCO Project 100 000 -100 000 0
TOTAL 15 498 748 1 575 -100 000 15 400 323
Expenditure (direct costs by programme commitments)
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget
EPI 2 037 574 2 072 574 2 071 511 300 615 317 197 307 869 2 338 189 2 389 771 2 379 380
RES 1 227 210 1 154 210 1 153 387 154 941 189 926 179 626 1 382 151 1 344 136 1 333 013
SCD 420 626 353 626 352 858 102 000 94 905 79 387 522 626 448 531 432 245
Reitox subvention 2 594 497 2 487 086 2 487 086
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 2 — Functioning allocated Title 2  
Functioning  
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Communication 885 111 885 111 846 846 90 000 81 398 79 840 1 043 356 1 143 563 1 114 032 2 018 467 2 110 072 2 040 718
Reitox 754 622 674 622 659 182 0 0 0 190 000 158 630 151 626 944 622 833 252 810 808
Programme
Title 1 — Salaries allocated Title 1  
Salaries 
executed
Title 2 — Functioning allocated Title 2  
Functioning  
executed
Title 3 — Activities allocated Title 3  
Activities  
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Direction 807 980 797 980 795 217 0 0 0 210 000 178 752 168 771 1 017 980 976 732 963 988
Administration 1 857 845 2 017 345 2 016 081 1 446 480 1 464 788 1 399 848 56 400 42 400 39 330 3 425 725 3 589 533 3 543 325
Administration (training and recruitment) 65 000 65 000 88 066
ICT 653 032 688 532 688 143 581 459 520 753 507 439 20 000 11 925 6 088 1 254 491 1 221 210 1 201 670
Programme Title 1 — Salaries
Title 1  
Salaries 
executed
Title 2 — Functioning
Title 2  
Functioning  
executed
Title 3 — Activities
Title 3  
Activities  
executed
Total programme direct costs
Total programme 
direct costs 
executed
IPA 3 85 000 46 031 2 500 0 412 500 379 112 500 000 425 143
General	report	of	activities	2010
96
Budget outturn account for the financial year 2010: Economic outturn account
2010 2009
Revenue
Commission subsidy (for the operating budget — Titles 1,2 and 3 of the agency) + 15 362 000.00 14 150 000.00
Phare funds from Commission +
Other contributions and funding received via the Commission (IPA 3) + 500 000.00 450 810.00
Other donors (Norway Grant) + 383 886.11 376 795.00
Fee income +
Other revenue + 27 596.40 205 798.31
Total revenue (a) 16 273 482.51 15 183 403.31
Expenditure
Title I:Staff
Payments - 8 722 153.46 8 413 498.37
Appropriations carried over - 65 673.61 59 408.05
Title II: Administrative expenses
Payments - 1 655 059.82 976 986.47
Appropriations carried over - 342 394.60 345 408.94
Title III: Operating expenditure 
Payments - 4 495 449.90 5 261 522.49
Appropriations carried over - 303 559.61 371 141.68
Total expenditure (b) 15 584 291.00 15 427 966.00
Outturn for the financial year (a-b) 689 191.51 -244 562.69
Cancellation of unused payment appropriations carried over from previous year + 61 824.94 136 601.01
Adjustment for carry-over from the previous year of appropriations available at 31.12 
arising from assigned revenue + 383 981.74 626 438.16
Exchange differences for the year (gain +/loss -) +/- 209.12 779.15
Adjust. Norway grant prorata 2010 + Decommitment + last instalments final CARDS, IPA1 
and IPA2 + Outturn Norway 2008–09 -134 835.65 -292 089.50
Balance of the outturn account for the financial year 2010 
(including balance outturn from 2009 and 2008) 1 000 371.66 227 166.13
Balance year N-1 +/- 227 166.13
Positive balance from year N-1 reimbursed in year N to the Commission - -227 166.13
Balance year 2010 relating to N-1 and N-2 ( 2009 and 2008 amending budget) 362 000.00
Positive balance from year N-1 and N-2 ( 2009 and 2008) to be reimbursed to the 
Commission 362 000.00
Result used for determining amounts in general accounting 1 000 371.66 227 166.13
Commission subsidy — agency registers accrued revenue and Commission accrued 
expense 14 361 628.34
Pre-financing remaining open to be reimbursed by agency to Commission in year N+1 1 000 371.66
Not included in the budget outturn:
Interest generated by 31/12/N on the Commission subsidy funds and to be reimbursed to 
the Commission (liability) + 14 533.27 30 643.36
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2010 budget appropriations and execution by nature of expenditure
Financial and accounting management
A budget of EUR 15 900 323 was adopted for the implementation of the 2010 Work 
programme. The budgetary figures for 2010 are presented in the tables below.
Budgetary provisions and appropriations, 2010
Title Description EUR
1. Expenditure relating to persons working with the office 
• Staff in active employment
•  Other staff-related expenditure (exchange of officials, etc.)
 
8 651 154
57 846
Total under Title 1 8 709 000
2. Buildings, equipment and sundry operating expenditure 
•  Investment in immovable property, rental of buildings and associated costs
•  Data processing
•  Movable property and associated costs
•  Current administrative expenditure + postal charges and 
telecommunications
•  Socio-medical infrastructure
 
1 169 353
516 161
119 356
235 753
 
26 316
Total under Title 2 2 066 939
3. Expenditure resulting from special functions carried out by the institution
•  Statutory meetings
•  Expenditure on formal and others meetings + representative expenses
•  Studies, surveys, consultations 
•  Publishing
•  European Network on Drugs and Drug Addiction (Reitox)
•  Missions
 
250 000
349 927
156 290
1 044 176
2 487 086
336 905
Total under Title 3 4 624 384
Total core budget 15 400 323
4. Expenditure relating to other subsidies
•  EC financing of specific projects
•  IPA3 financing for implementing pre-accession strategy
10. Other expenses (reserve) 500 000
Total budget 15 900 323
Execution of the budget: credit consumption (commitments), 2010
Title Description % consumption  of available credits
1. Staff
Staff salaries, allowances, etc.
99.87 %
2. Buildings, equipment and sundry operating expenditure 96.14 %
3. Operating expenditure 98.04 %
4. Expenditure relating to other subsidies
Total consumption (Titles 1, 2, 3 ) 98.82 %
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EMCDDA balance sheet at 31 December 2010
Assets
31.12.2010 31.12.2009 Variation
A. Non–current assets
Intangible fixed assets 156 953.91 301 868.74 -144 914.83
Tangible fixed assets 2 488 414.54 2 625 036.07 -136 621.53
Land and buildings 2 176 027.28 2 267 516.80 -91 489.52
Plant and equipment 78 932.35 32 766.36 46 165.99
Computer hardware 133 132.4 198 221.29 -65 088.89
Furniture and vehicles 100 322.51 126 531.62 -26 209.11
Total non–current assets 2 645 368.45 2 926 904.81 -281 536.36
B. Current assets
Short-term pre-financing 11 600 0.00 11 600.00
Short-term pre-financing 11 600 0.00 11 600.00
Short-term receivables 325 558.64 655 360.74 -329 802.10
Current receivables 183 435.29 558 238.93 -374 803.64
Other 142 123.35 97 121.81 45 001.54
Accrued income 0 27 661.76 -27 661.76
Deferred charges 142 123.35 69 460.05 72 663.30
Cash and cash equivalents 2 056 532.41 1 255 148.58 801 383.83
Total current assets 2 393 691.05 1 910 509.32 483 181.73
Total assests 5 039 059.5 4 837 414.13 201 645.37
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Liabilities
31.12.2010 31.12.2009 Variation
A. Net assets 2 091 708.92 2 923 169.36 -831 460.44
Accumulated surplus/deficit 2 923 169.36 3 259 134.41 -335 965.05
Economic result of the year — profit +/loss -831 460.44 -335 965.05 -495 495.39
C. Non–current liabilities 0.00 70 000.00 -70 000.00
Provisions for risks and charges 0.00 70 000.00 -70 000.00
Total 2 091 708.92 2 993 169.36 -901 460.44
D. Current liabilities 2 947 350.58 1 844 244.77 1 103 105.81
Accounts payable 2 947 350.58 1 844 244.77 1 103 105.81
Current payables 124 050.31 31 874.46 92 175.85
Other 1 602 967.10 1 550 390.18 52 576.92
Accrued charges 1 571 684.77 1 533 953.29 37 731.48
Deferred income 31 282.33 16 436.89 14 845.44
Accounts payable with consolidated EU entities 1 220 333.17 261 980.13 958 353.04
Pre-financing received from consolidated EU entities 1 203 389.06 227 166.13 976 222.93
Other accounts payable against consolidated EU entities 16 944.11 34 814.00 -17 869.89
Total current liabilities 2 947 350.58 1 844 244.77 1 103 105.81
Total liabilities 5 039 059.50 4 837 414.13 201 645.37
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Budget outturn account for the financial year 2010: revenue and expenditure
2010 2009 Variation
Contributions of EFTA countries belonging to the EEA 369 040.67 360 358.11 8 682.56
Recovery of expenses 19 220.09 6 757.60 12 462.49
Revenues from administrative operations 31 835.86 526 789.08 -494 953.22
Other operating revenue 14 515 938.66 14 941 017.87 -425 079.21
Total operating revenue 14 936 035.28 15 834 922.66 -898 887.38
Administrative expenses -10 984 345.32 -10 738 372.13 -245 973.19
All staff expenses -8 555 136.60 -8 487 911.01 -67 225.59
Fixed asset related expenses -435 547.88 -449 685.20 14 137.32
Other administrative expenses -1 993 660.84 -1 800 775.92 -192 884.92
Operational expenses -4 779 091.02 -5 430 022.69 650 931.67
Other operational expenses 4 779 091.02 -5 430 022.69 10 209 113.71
Total operating expenses -15 763 436.34 -16 168 394.82 404 958.48
Surplus/(deficit) from operating activities -827 401.06 -333 472.16 -493 928.90
Financial expenses -4 059.38 -2 492.89 -1 566.49
Surplus/ (deficit) from non operating activities -4 059.38 -2 492.89 -1 566.49
Surplus/(deficit) from ordinary activities -831 460.44 -335 965.05 -495 495.39
Economic result of the year -831 460.44 -335 965.05 -495 495.39
List of 2010 negotiated procedures
Supplies Services Total
Number of 
contracts
Volume of 
contracts  
(EUR)
Number of 
contracts
Volume of 
contracts  
(EUR)
Number of 
contracts %
Volume  
of contracts 
(EUR)
%
>5 000 & <25 000 EUR 4 28 200.05 29 271 505.50 33 87 % 299 705.55 83.5 %
=/> 25 000 EUR 0 0.00 2 59 144.20 2 13 % 59 144.20 16.5 %
TOTAL 4 28 200.05 31 330 649.70 35 100 % 358 849.75 100 %
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Annex 8 
List of acronyms and abbreviations
ABAC-SAP EC budget and accrual-based accountancy system
AIDS Acquired Immune Deficiency Syndrome
AR EMCDDA Annual report
CEPOL European Police College
CICAD Inter-American Drug Abuse Control Commission
CMA content management application
CND UN Commission on Narcotic Drugs
COM EMCDDA Communication unit
CUP Cross Unit Project
DG SANCO Directorate-General of Health and Consumer Protection
DRD drug-related deaths
DRID drug-related infectious diseases
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDND European Database on New Drugs
ELDD European Legal Database on Drugs
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMA European Medicines Agency
EMQ European Model Questionnaire
ENP European Neighbourhood Policy
EP European Parliament
EPI Prevalence, consequences and data management unit of the EMCDDA
ESPAD European School Survey Project on Alcohol and Drugs
EU European Union
EU-LAC European Union–Latin America and the Caribbean
EUROLIB a grouping of European institutional libraries
EWS Early warning system
GP general practitioner
GPS General population surveys
GRA General report of activities
GRADE  Grading of Recommendations Assessment, Development and Evaluation 
working group
HBSC Health Behaviour in School-aged Children (WHO study)
HCIN Heads of Communication and Information Network
HCV Hepatitis C virus
HDG Horizontal Drugs Group
HIV Human Immunodeficiency Virus
IATE Inter Active Terminology for Europe (multilingual database of terms)
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MB Management Board
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About the EMCDDA
The	European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	(EMCDDA)	
is	one	of	the	European	Union’s	decentralised	agencies.	Established	in	1999	
and	based	in	Lisbon,	it	is	the	central	source	of	comprehensive	information	
on	drugs	and	drug	addiction	in	Europe.	
The	EMCDDA	collects,	analyses	and	disseminates	factual,	objective,	reliable	
and	comparable	information	on	drugs	and	drug	addiction.	In	doing	so,	it	
provides	its	audience	with	an	evidence-based	picture	of	the	drug	
phenomenon	at	European	level.
The	Centre’s	publications	are	a	prime	source	of	information	for	a	wide	
range	of	audiences	including	policymakers	and	their	advisors;	professionals	
and	researchers	working	in	the	drugs	field;	and,	more	broadly,	the	media	
and	general	public.
The	General	report	of	activities	is	an	annual	publication	providing	a	
detailed	progress	report	of	the	EMCDDA’s	activities	over	a	12-month	
period.	Published	every	spring,	it	catalogues	the	Centre’s	achievements	in	
each	area	of	its	annual	Work	programme.	The	report	is	a	useful	
information	source	for	all	those	seeking	comprehensive	information	on	the	
Centre	and	its	work.
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